<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pharm Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharm. Res</journal-id>
<journal-title-group>
<journal-title>Pharmaceutical Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0724-8741</issn>
<issn pub-type="epub">1573-904X</issn>
<publisher>
<publisher-name>Springer US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32377929</article-id>
<article-id pub-id-type="pmc">7203094</article-id>
<article-id pub-id-type="publisher-id">2826</article-id>
<article-id pub-id-type="doi">10.1007/s11095-020-02826-8</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Expert Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>L-Type amino acid transporter 1 as a target for drug delivery</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1769-389X</contrib-id>
<name>
<surname>Puris</surname>
<given-names>Elena</given-names>
</name>
<address>
<email>elena.puris@uni-heidelberg.de</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gynther</surname>
<given-names>Mikko</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Auriola</surname>
<given-names>Seppo</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huttunen</surname>
<given-names>Kristiina M.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.9668.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0726 2490</institution-id><institution>School of Pharmacy, </institution><institution>University of Eastern Finland, </institution></institution-wrap>P.O. Box 1627, FI-70211 Kuopio, Finland </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.7700.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 4373</institution-id><institution>Institute of Pharmacy and Molecular Biotechnology, </institution><institution>Ruprecht-Karls-University, </institution></institution-wrap>69120 Heidelberg, Germany </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>6</day>
<month>5</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>6</day>
<month>5</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2020</year>
</pub-date>
<volume>37</volume>
<issue>5</issue>
<elocation-id>88</elocation-id>
<history>
<date date-type="received">
<day>4</day>
<month>3</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>4</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2020</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Our growing understanding of membrane transporters and their substrate specificity has opened a new avenue in the field of targeted drug delivery. The L-type amino acid transporter 1 (LAT1) has been one of the most extensively investigated transporters for delivering drugs across biological barriers. The transporter is predominantly expressed in cerebral cortex, blood-brain barrier, blood-retina barrier, testis, placenta, bone marrow and several types of cancer. Its physiological function is to mediate Na<sup>+</sup> and pH independent exchange of essential amino acids: leucine, phenylalanine, etc. Several drugs and prodrugs designed as LAT1 substrates have been developed to improve targeted delivery into the brain and cancer cells. Thus, the anti-parkinsonian drug, L-Dopa, the anti-cancer drug, melphalan and the anti-epileptic drug gabapentin, all used in clinical practice, utilize LAT1 to reach their target site. These examples provide supporting evidence for the utility of the LAT1-mediated targeted delivery of the (pro)drug. This review comprehensively summarizes recent advances in LAT1-mediated targeted drug delivery. In addition, the use of LAT1 is critically evaluated and limitations of the approach are discussed.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>drug delivery systems</kwd>
<kwd>L-type amino acid transporter 1</kwd>
<kwd>membrane transporter</kwd>
<kwd>targeting</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>Academy of Finland</institution>
</funding-source>
<award-id>294227, 307057</award-id>
<principal-award-recipient>
<name>
<surname>Huttunen</surname>
<given-names>Kristiina M.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005440</institution-id>
<institution>Keski-Suomen Rahasto</institution>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008969</institution-id>
<institution>Alfred Kordelinin Säätiö</institution>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007753</institution-id>
<institution>Itä-Suomen Yliopisto</institution>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer Science+Business Media, LLC, part of Springer Nature 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par35">The main aim of targeted drug delivery is to achieve therapeutic concentrations of the drug at the site of action in the tissue of interest to produce the desired pharmacological effect as well as minimizing the side effects caused by drug distribution to other organs. Delivery of the drug to the site where the target is located requires knowledge about the tissue and an understanding of what features the drug should possess in order to be selectively distributed. In addition to direct administration of the drug by some specific route to the target organ, several other strategies have been investigated including nanoparticle-based drug delivery systems, prodrugs or derivatives and stimuli sensitive targeted therapy (<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>).</p>
<p id="Par36">One of the most promising approaches is the utilization of the transporters selectively expressed at the cell membrane of the target tissue (<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>). The design of drugs or prodrugs as substrates of the particular membrane transporter can enable targeted delivery of the drug based on the tissue specific expression profile of the carrier. In this respect, the L-type amino acid transporter 1 (LAT1, SLC7A5), which is expressed at a relatively high level at the blood-brain barrier (BBB), blood-retinal barrier (BRB), testis, bone marrow, placenta and several types of human tumour is an intriguing way for targeting a drug to these organs. Importantly, the transporter has already demonstrated its utility by mediating the brain delivery of the antiparkinsonian drug L-Dopa and the anticancer drug, melphalan (<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref>). This suggests that effective drug delivery to the target organ expressing LAT1 can be achieved by rational design of the drugs mimicking the structures of the transporter endogenous substrates.</p>
<p id="Par37">In the present review, the current state of the art and recent improvements in the LAT1-mediated drug delivery are summarized. In addition, the limitations and advantages of the approach are discussed.</p>
</sec>
<sec id="Sec2">
<title>LAT1 and its function</title>
<p id="Par38">The L-type amino acid transporter 1 is a Na<sup>+</sup>- and pH-independent exchanger of large branched-chain and aromatic neutral amino acids with 1:1 stoichiometry (<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref>). The transporter consists of two subunits covalently linked via a disulfide bond (<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref>). The light chain subunit (LAT1, SLC7A5) is a functional subunit responsible for the exchange of amino acids (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). The heavy chain subunit (known as CD98 or 4F2hc, SLC3A2) is a glycoprotein coupled with the light chain subunit which acts as a molecular chaperone localizing LAT1 at the plasma membrane. In addition, it is involved in the processes of cell survival and integrin activation. Recently, a cryo-electron microscopy study investigating the structure of the complex LAT1-4F2hc (hereinafter referred to as LAT1) revealed that in addition to a disulfide bond association, the light chain subunit cooperates extensively with 4F2hc on the extra- and intracellular side of the membrane as well as within the membrane (<xref ref-type="bibr" rid="CR12">12</xref>). The authors concluded that the heavy chain subunit was crucial for the transport function of the complex (<xref ref-type="bibr" rid="CR12">12</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Heterodimeric transporter LAT1/4F2hc - mediated transport of essential (histidine, isoleucine, methionine, tryptophan, phenylalanine, leucine, cysteine, tyrosine) and non-essential (glutamine) amino acids across the cell membrane.</p></caption><graphic id="MO1" xlink:href="11095_2020_2826_Fig1_HTML"></graphic></fig></p>
<p id="Par39">The transporter is responsible for the inward flux of several essential amino acids such as phenylalanine, leucine, isoleucine, tryptophan, histidine, tyrosine in antiport with histidine, tyrosine and a non-essential amino acid glutamine (Fig. <xref ref-type="fig" rid="Fig1">1</xref>) (<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR15">15</xref>). While the affinity of the essential amino acids for LAT1 is high (<italic>K</italic><sub>m</sub> values for the human isoform range from 14 to 28 μM) (<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR16">16</xref>), the non-essential glutamine showed lower affinity (<italic>K</italic><sub>m</sub> 1.6 mM) to human LAT1. The intracellular accumulation of glutamine acting as an exchanger for essential amino acids is mediated by the transporters of system N and A (<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref>). In addition to amino acid transport, LAT1 plays a role in the passage of thyroid hormones, i.e. triiodothyronine and thyroxine (<xref ref-type="bibr" rid="CR18">18</xref>).</p>
<p id="Par40">The LAT1 plays a crucial role in normal body functioning by regulating the exchange of the amino acids which take part in the synthesis of peptides, proteins and neurotransmitters as well as in nutrient metabolism. Thus, while developing LAT1-mediated drug delivery systems for targeting non-tumorous tissue, it is important that the vital function of the transporter should not be disturbed. In contrast, as the transporter plays a crucial role in cancer cell growth and survival, a strategy to affect the function and expression of LAT1 in a tumour has been investigated and considered as a promising treatment approach (<xref ref-type="bibr" rid="CR19">19</xref>). More information regarding the structure, function, transport mechanism and homology modelling of LAT1 can be found in recently published studies and reviews (<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR26">26</xref>).</p>
</sec>
<sec id="Sec3">
<title>Tissue expression of LAT1</title>
<p id="Par41">The localization and mRNA/protein expression of the light chain subunit LAT1 in specific human tissues according to the Human Protein Atlas (<xref ref-type="bibr" rid="CR27">27</xref>) is summarized in Table <xref ref-type="table" rid="Tab1">I</xref>. The mRNA expression of the LAT1 differs in the 27 studied human tissues with the highest expression present in the cerebral cortex, retina, esophagus, testis, placenta and bone marrow (<xref ref-type="bibr" rid="CR27">27</xref>). LAT1 is primarily localized in the basolateral membrane of polarized epithelia (<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref>). The highest levels of LAT1 protein expression of LAT1 were detected in parathyroid and adrenal glands, salivary gland, esophagus, bronchus, kidney, urinary bladder, bone marrow, appendix, testis, heart muscle, fallopian tube, cervix, gastrointestinal tract, smooth muscle and gallbladder (Table <xref ref-type="table" rid="Tab1">I</xref>).<table-wrap id="Tab1"><label>Table I</label><caption><p>The Localization and mRNA/Protein Expression of LAT1 in Human Tissues According to the Human Protein Atlas (<xref ref-type="bibr" rid="CR27">27</xref>)</p></caption><table frame="hsides" rules="groups"><thead><tr><th><bold>Tissue</bold></th><th><bold>mRNA*</bold></th><th><bold>Protein</bold></th></tr></thead><tbody><tr><td>Cerebral cortex including endothelial cells and neurons, cerebellum</td><td>15.9–45.8</td><td>medium</td></tr><tr><td>Olfactory region, hippocampus, amygdala, thalamus, hypothalamus, midbrain, pons and medulla, corpus callosum, spinal cord</td><td>9.6–24.5</td><td>N/A</td></tr><tr><td>Basal ganglia</td><td>24.5</td><td>low</td></tr><tr><td>Retina</td><td>34.9</td><td>N/A</td></tr><tr><td>Thyroid gland</td><td>4.2</td><td>medium</td></tr><tr><td>Parathyroid and adrenal glands</td><td>1.5–3.2</td><td>high</td></tr><tr><td>Pituitary gland</td><td>9.0</td><td>N/A</td></tr><tr><td>Salivary gland and esophagus</td><td>11.5–38.7</td><td>high</td></tr><tr><td>Oral mucosa</td><td>N/A</td><td>medium</td></tr><tr><td>Tongue</td><td>16.7</td><td>N/A</td></tr><tr><td>Nasopharynx</td><td>N/A</td><td>medium</td></tr><tr><td>Bronchus</td><td>N/A</td><td>high</td></tr><tr><td>Lung</td><td>3.8</td><td>medium</td></tr><tr><td>Kidney and urinary bladder</td><td>3.6–11.5</td><td>high</td></tr><tr><td>Gastrointestinal tract: stomach, duodenum, small intestine, colon, rectum</td><td>3.4–12.7</td><td>high</td></tr><tr><td>Epididymis, seminal vesicle and prostate</td><td>4.3–30.4</td><td>medium</td></tr><tr><td>Testis</td><td></td><td>high</td></tr><tr><td>Ovary, endometrium, placenta and breast</td><td>4.3–28.4</td><td>medium</td></tr><tr><td>Fallopian tube and cervix</td><td>3.3–7.9</td><td>high</td></tr><tr><td>Heart muscle</td><td>8.2</td><td>high</td></tr><tr><td>Skeletal muscle</td><td>11.2</td><td>medium</td></tr><tr><td>Smooth muscle</td><td>4.8</td><td>high</td></tr><tr><td>Adipose tissue</td><td>8.2</td><td>N/A</td></tr><tr><td>Liver and gallblader</td><td>9.7</td><td>medium</td></tr><tr><td>Gallblader</td><td>6.4</td><td>high</td></tr><tr><td>Skin</td><td>10.7</td><td>medium</td></tr><tr><td>Lymph node</td><td>11.1</td><td>low</td></tr><tr><td>Spleen and tonsil</td><td>6.4–15.0</td><td>medium</td></tr><tr><td>Bone marrow</td><td>71.2</td><td>high</td></tr><tr><td>Thymus</td><td>3.7</td><td>N/A</td></tr><tr><td>Appendix</td><td>14.7</td><td>high</td></tr><tr><td>Blood cells including granulocytes, T- and B-cells, NK cells, dendritic cells</td><td>0.2–15.9</td><td>N/A</td></tr></tbody></table><table-wrap-foot><p>N/A – no data available</p><p>*- normalized expression levels.</p></table-wrap-foot></table-wrap></p>
<p id="Par42">In the endothelial cells of the brain microvessels, LAT1 is expressed on both apical and basolateral sides of the cell membranes (<xref ref-type="bibr" rid="CR30">30</xref>). Additionally, LAT1 expression was detected in brain parenchymal cells such as human and mouse astrocytes, mouse and rat neurons and immortalized microglia cultures (<xref ref-type="bibr" rid="CR31">31</xref>–<xref ref-type="bibr" rid="CR33">33</xref>). LAT1 is also expressed in the inner BRB, ensuring the flux of large neutral amino acids and neurotransmitters (<xref ref-type="bibr" rid="CR34">34</xref>).</p>
<p id="Par43">Furthermore, LAT1 is overexpressed in human tumors such as cholangiocarcinoma, malignant glioma, multiple myeloma, and lung, bladder, bone, pancreas, thyroid, prostate, uterine cervical, breast cancer and other malignancies as compared to benign tissue used as the control (<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR35">35</xref>–<xref ref-type="bibr" rid="CR37">37</xref>). The association between LAT1 overexpression and meaningfully shorter survival in many types of cancer have indicated that the transporter may be exploited as a prognostic biomarker to predict the outcome in different cancer types (<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref>).</p>
<p id="Par44">The protein expression of LAT1 in the majority of the listed tissues has been also confirmed, although quantitative information about the absolute protein expression is still limited. Importantly, the protein expression of LAT1 can vary between species, which should be taken into account during the development of LAT1-utilizing (pro)drugs. For instance, in isolated cortex microvessels, the protein expression in rats (3.00 ± 0.62 fmol/μg protein) and mice (2.19 ± 0.21 fmol/μg protein) was higher than in humans (0.43 ± 0.09 fmol/μg protein) (<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref>).</p>
<p id="Par45">There is a correlation between the mRNA expressions of the heavy chain SLC3A2 and light chain SLC7A5 in human tissues. Similarly to SLC7A5, the highest levels of SLC3A2 mRNA expression were found in cerebral cortex, placenta, testis and bone marrow (<xref ref-type="bibr" rid="CR27">27</xref>). This correlation hints at the presence of an interaction between the subunits. Additionally, high SLC3A2 expression has been detected in other tissues, i.e. parathyroid gland and kidney, where the heavy chain is responsible for localizing other SLC7 transporters at the cell membrane (<xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR29">29</xref>).</p>
</sec>
<sec id="Sec4">
<title>LAT1 and diseases</title>
<p id="Par46">The expression and function of LAT1 can be altered in pathological conditions, such as cancer and central nervous system (CNS) diseases and consequently, this can lead to altered efficacy of LAT1-mediated drug delivery to the target organ.</p>
<p id="Par47">Thus, overexpression of LAT1 in human brain metastasis in comparison to non-tumoral brains correlated to increased uptake of LAT1 substrate 6-[<sup>18</sup>F]-fluoro-L-3,4-dihydroxy-phenylalanine ([<sup>18</sup>F]-DOPA) (<xref ref-type="bibr" rid="CR33">33</xref>). In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated mouse model of Parkinson’s disease, mRNA expression of LAT1 at the BBB was significantly reduced, although this was not reflected in the protein expression level of the transporter (<xref ref-type="bibr" rid="CR42">42</xref>). In addition, the loss of LAT1 due to mutations leads to impairment of amino acid homeostasis in the brain and therefore it has been suggested to be a cause of motor dysfunction and Autism Spectrum Disorder in mice and human (<xref ref-type="bibr" rid="CR43">43</xref>). Recently, Gynther et al. (2018) showed that LAT1 function was not altered at the BBB of lipopolysaccharide (LPS) induced neuroinflammation murine model and in the transgenic Alzheimer’s disease model with amyloid precursor protein (<italic>APP</italic>) and presenilin (<italic>PSEN1</italic>) gene mutations, (<xref ref-type="bibr" rid="CR31">31</xref>). In the same study, LAT1 protein expression and function were similar in wild type astrocytes with and without LPS treatment and in <italic>APP/PS1</italic> transgenic astrocytes treated with LPS (<xref ref-type="bibr" rid="CR31">31</xref>).</p>
<p id="Par48">Furthermore, as previously mentioned due to upregulated LAT1 expression in several human cancers and its role in tumour cell growth and survival, the transporter has been considered as the potential target for anticancer therapy. The LAT1 inhibition as a strategy for cancer treatment has been summarized in several excellent reviews (<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR44">44</xref>–<xref ref-type="bibr" rid="CR47">47</xref>). In addition, Cibrian et al. (2020) demonstrated that LAT1 expression was upregulated in keratinocytes and skin infiltrating lymphocytes of psoriatic lesions in human subjects and mice (<xref ref-type="bibr" rid="CR48">48</xref>). The authors considered targeting LAT1 as a potential immunosuppressive strategy to regulate skin inflammation driven by the interleukin IL-23/IL-1b/IL-17 axis (<xref ref-type="bibr" rid="CR48">48</xref>).</p>
</sec>
<sec id="Sec5">
<title>Drug delivery via LAT1</title>
<sec id="Sec6">
<title>Substrate specificity</title>
<p id="Par49">One obstacle to the development of LAT1-utilizing compounds can be the potential inhibition of their uptake due to competition with amino acids. The essential amino acids are delivered into the brain mainly from the blood after dietary intake, while non-essential amino acids are synthetized inside the brain. Thus, the food or supplements containing high amounts of essential amino acids or protein can alter the delivery of LAT1 utilizing (pro)drugs. For instance, the brain uptake of L-Dopa, a substrate of LAT1, was decreased after a high-protein meal or the intravenous infusion of large neutral amino acids before the administration of the drug in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine parkinsonian monkeys (<xref ref-type="bibr" rid="CR49">49</xref>). Nonetheless, the pilot study of Cucca et al. (2015) demonstrated that a six-month amino acid supplementation in protein-restricted patients with Parkinson’s disease, chronically treated with L-Dopa, did not affect neurological parameters (<xref ref-type="bibr" rid="CR50">50</xref>).</p>
<p id="Par50">The efficient utilization of LAT1 for drug delivery requires the rational design and development of compounds which can consequently compete with millimolar concentrations of amino acids. One of the strategies to overcome this issue is to develop (pro) drugs with higher affinity (<italic>K</italic><sub><italic>m</italic></sub>) to LAT1 as compared to that of the endogenous amino acid substrates. In this respect, it is important to gather knowledge about substrate specificity and an understanding of ligand - transporter interactions. Despite the relatively low maximal transport rate (<italic>V</italic><sub><italic>max</italic></sub>) enabling the substrate compounds to cross the cellular membrane per unit time, the amino acid-resembling (pro) drugs have demonstrated a potential to utilize the transporter for CNS and cancer delivery.</p>
<p id="Par51">Several studies investigating the development of LAT1 substrate structure-activity relationship have been conducted (<xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR51">51</xref>–<xref ref-type="bibr" rid="CR55">55</xref>). The findings suggest that binding to LAT1 requires the presence of both the amino and carboxylic acid functional groups as well as large, neutral side groups. In addition, the presence of aromaticity in the compound molecule, for instance in a prodrug promoiety such as phenylalanine, plays an important role in the binding to LAT1 and its ability to utilize transporter for cellular uptake (<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref>).</p>
<p id="Par52">Importantly, it has been demonstrated that the affinity (<italic>K</italic><sub>m</sub>) to LAT1 of L-enantiomers of phenylalanine and leucine was higher as compared to the corresponding D-enantiomers. In contrast, the transport rate (<italic>V</italic><sub>max</sub>) was similar for L and D-enantiomers (<xref ref-type="bibr" rid="CR16">16</xref>). In the study of Chien et al. (2018), the authors concluded that LAT1 is not stereoselective in terms of the transport rate of the amino acids, whereas based on the relative IC<sub>50</sub>-values of L- and D-enantiomers of amino acid, there is variation in their binding to the transporter (<xref ref-type="bibr" rid="CR58">58</xref>).</p>
<p id="Par53">In addition, LAT1 has overlapping substrate specificity with other amino acid transporters, for instance LAT2 (<xref ref-type="bibr" rid="CR20">20</xref>), which can complicate the development of LAT1 selective compounds for the targeted delivery.</p>
</sec>
<sec id="Sec7">
<title>Brain delivery of CNS-acting drugs</title>
<p id="Par54">The comparatively high expression of LAT1 transporter on both the luminal and abluminal sides of the brain capillary endothelial cells as well as on brain parenchymal cells offers a promising opportunity for LAT1-mediated brain delivery of CNS drugs. The transporter has demonstrated its efficacy in the delivery of clinically used CNS drugs and prodrugs such as L-Dopa (Fig. <xref ref-type="fig" rid="Fig2">2A</xref>), baclofen (Fig. <xref ref-type="fig" rid="Fig2">2B</xref>), alpha-methyldopa (Fig. <xref ref-type="fig" rid="Fig2">2C</xref>) gabapentin (Fig. <xref ref-type="fig" rid="Fig2">2D</xref>) (<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR60">60</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Chemical structures, molecular weight (MW) and logP of amino acid CNS drugs and derivatives designed to utilize LAT1 (part 1): L-Dopa (<bold>a</bold>), baclofen (<bold>b</bold>), alpha-methyldopa (<bold>c</bold>) gabapentin (<bold>d</bold>), derivative of phosphonoformate (<bold>e</bold>), derivative of nipecotic acid (<bold>f</bold>), derivative of L-tyrosine (<bold>g</bold>), derivatives of ketoprofen (<bold>h</bold>-<bold>l</bold>, <bold>n</bold>), derivative of 6-mercaptopurine (<bold>m</bold>), derivatives of valproic acid (<bold>o</bold>-<bold>u</bold>), derivatives of dopamine (<bold>v</bold>-<bold>x</bold>), derivative of benzoic acid (<bold>y</bold>). The values of logP were calculated using Marvin Sketch version 15.8.31 (ChemAxon, Budapest, Hungary)0</p></caption><graphic id="MO2" xlink:href="11095_2020_2826_Fig2_HTML"></graphic></fig></p>
<p id="Par55">Several attempts have been made to develop LAT1-utilizing derivatives and prodrugs sharing the structural features of the natural substrates. Some derivatives have demonstrated efficient LAT1-mediated cellular uptake and/or BBB permeation after <italic>in situ</italic> brain perfusion in rats and mice (<xref ref-type="bibr" rid="CR61">61</xref>–<xref ref-type="bibr" rid="CR66">66</xref>). In the majority of cases, a parent drug has been conjugated to the amino acid side chain via a biodegradable linker in such a way that carboxyl and amino groups are not substituted to allow effective LAT1 binding (Figs. <xref ref-type="fig" rid="Fig2">2</xref>, <xref ref-type="fig" rid="Fig3">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Chemical structures, molecular weight (MW) and logP of amino acid CNS drugs and derivatives designed to utilize LAT1 (part 2): derivatives of perforin inhibitor (<bold>a</bold>, <bold>b</bold>), derivatives of ketoprofen (<bold>c</bold>-<bold>f</bold>, <bold>j</bold>), derivatives of ferulic acid (<bold>g</bold>, <bold>i</bold>), derivative of acyclovir (<bold>k</bold>). The values of logP were calculated using Marvin Sketch version 15.8.31 (ChemAxon, Budapest, Hungary).</p></caption><graphic id="MO3" xlink:href="11095_2020_2826_Fig3_HTML"></graphic></fig></p>
<p id="Par56">Thus, the L-tyrosine derivative of antiviral phosphonoformate (Fig. <xref ref-type="fig" rid="Fig2">2E</xref>) synthetized by Walker et al. (1994) inhibited the uptake L-[<sup>3</sup>H]-tyrosine in porcine brain microvessel endothelial cells (<xref ref-type="bibr" rid="CR67">67</xref>) providing evidence of LAT1 binding. A tyrosine conjugate of another CNS agent, nipecotic acid (Fig. <xref ref-type="fig" rid="Fig2">2F</xref>), designed as a substrate of the amino acid transporter displayed a concentration-dependent anticonvulsant effect in a murine epilepsy model - Diluted Brown Agouti/2 mice (<xref ref-type="bibr" rid="CR68">68</xref>). In another study, <italic>p</italic>-nitro- and <italic>p</italic>-chlorobenzyl ether prodrugs of L-tyrosine (Fig. <xref ref-type="fig" rid="Fig2">2G</xref>) inhibited the uptake of L-[<sup>3</sup>H]-tyrosine in rabbit corneal cells (<xref ref-type="bibr" rid="CR69">69</xref>). Gynther et al. (2008) demonstrated LAT1-mediated delivery of an L-tyrosine prodrug of ketoprofen (Fig. <xref ref-type="fig" rid="Fig2">2H</xref>) across the BBB using the <italic>in situ</italic> rat brain perfusion technique, as the brain uptake of the prodrug was significantly decreased after co-perfusion with the competitive LAT1 inhibitor, 2-amino-2-norbornanecarboxylic acid (BCH) (<xref ref-type="bibr" rid="CR62">62</xref>). The ester- or amide-based ketoprofen prodrugs (Fig. <xref ref-type="fig" rid="Fig2">2I-L</xref>) conjugated to either phenylalanine or leucine did not show any binding to LAT1, as the brain uptake of L-[<sup>14</sup>C]-leucine was not altered after co-perfusion with these prodrugs in <italic>in situ</italic> brain perfusion in rats (<xref ref-type="bibr" rid="CR62">62</xref>). This provides additional evidence that the presence of α-carboxyl and α-amino groups as well as a nonpolar side chain in the structure of substrate of the transporter is important for binding to LAT1. Killian et al. (2007) covalently conjugated L-cysteine via a disulphide bond to 6-mercaptopurine (Fig. <xref ref-type="fig" rid="Fig2">2M</xref>) and showed that the prodrug significantly inhibited the uptake of L-[<sup>14</sup>C]-leucine across the BBB after <italic>in situ</italic> brain perfusion in rats, thereby demonstrating affinity to LAT1 (<xref ref-type="bibr" rid="CR63">63</xref>).</p>
<p id="Par57">The neuropharmacokinetic study of the LAT1-utilizing L-lysine derivative of ketoprofen (Fig. <xref ref-type="fig" rid="Fig2">2N</xref>) using a cerebral microdialysis technique in rats revealed for the first time that after crossing the BBB, the prodrug was predominantly distributed into the brain intracellular compartment and subsequently this was followed by the release of the parent drug (<xref ref-type="bibr" rid="CR61">61</xref>). Thus, the LAT1-mediated uptake of the prodrug was supported by the inhibition of the brain uptake of L-[<sup>14</sup>C]-leucine after <italic>in situ</italic> perfusion in rats, causing a reduction in the brain uptake of prodrug after co-perfusion with a LAT1 substrate, L-phenylalanine (<xref ref-type="bibr" rid="CR61">61</xref>). The ratio of unbound parent drug AUC in brain extracellular fluid to plasma was more than doubled after prodrug dosing as compared to ketoprofen itself given as an i.v. bolus injection in rats (<xref ref-type="bibr" rid="CR61">61</xref>). In addition, the estimated brain intracellular delivery efficacy evaluated as the AUC ratio of unbound parent drug in the brain intracellular compartment to plasma was significantly higher after prodrug dosing (21.8) in comparison to parent drug administration (0.06) (<xref ref-type="bibr" rid="CR61">61</xref>). In another study, Peura et al. (2011) synthetized several LAT1-utilizing prodrugs of valproic acid and showed that <italic>meta-</italic>substituted amide- and ester-based phenylalanine derivatives (Fig. <xref ref-type="fig" rid="Fig2">2O, P</xref>) had 10-fold higher affinity to LAT1 in comparison with the <italic>para</italic>-substituted conjugates as demonstrated by inhibition of L-[<sup>14</sup>C]-leucine brain uptake by prodrugs after <italic>in situ</italic> brain perfusion in rats (Fig. <xref ref-type="fig" rid="Fig2">2Q, R</xref>) (<xref ref-type="bibr" rid="CR65">65</xref>). Importantly, the amide-based <italic>meta</italic>-substituted prodrug (Fig. <xref ref-type="fig" rid="Fig2">2P</xref>) displayed 2-fold greater permeation rate across the BBB as compared to the <italic>para</italic>-substituted prodrug of valproic acid (Fig. <xref ref-type="fig" rid="Fig2">2R</xref>) as evaluated with <italic>in situ</italic> brain perfusion in rats (<xref ref-type="bibr" rid="CR65">65</xref>). Furthermore, the ability to bind to LAT1 was investigated for these prodrugs (Fig. <xref ref-type="fig" rid="Fig2">2O-R</xref>) as well as for amide- and ester-based prodrugs of valproic acid (Fig. <xref ref-type="fig" rid="Fig2">2S,T</xref>) conjugated to phenylalanine with an additional methylene group and tryptophan prodrug of valproic acid (Fig. <xref ref-type="fig" rid="Fig2">2U</xref>) (<xref ref-type="bibr" rid="CR70">70</xref>). The study demonstrated that the prodrugs inhibited the uptake of the LAT1 substrate L-[<sup>14</sup>C]-leucine in human breast cancer MCF-7 cells i.e. evidence of binding to LAT1. In addition, in pharmacokinetic study in rats, after a single i.v. bolus injection, amide-based prodrugs of valproic acid (Fig. <xref ref-type="fig" rid="Fig2">2P,R,S</xref>) crossed the BBB and released the parent drug, although the extent of brain delivery of valproic acid was not improved (<xref ref-type="bibr" rid="CR70">70</xref>). Thus, the brain AUC and C<sub>max</sub> of the parent drug released after dosing with the prodrugs was more than 7 times lower than those after valproic acid administration (<xref ref-type="bibr" rid="CR70">70</xref>). In another study, Peura et al. (2013) showed that the <italic>meta</italic>-substituted phenylalanine prodrug of dopamine (Fig. <xref ref-type="fig" rid="Fig2">2W</xref>) was able to cross the BBB using LAT1, as the prodrug significantly inhibited the brain uptake of L-[<sup>14</sup>C]-leucine and its own brain uptake was reduced after co-perfusion with L-phenylalanine after <italic>in situ</italic> brain perfusion in rat (<xref ref-type="bibr" rid="CR64">64</xref>). In contrast, the aspartic and adipic acid conjugates of dopamine (Fig. <xref ref-type="fig" rid="Fig2">2V,X</xref>) did not reach the brain as assessed with <italic>in situ</italic> brain perfusion in rat (<xref ref-type="bibr" rid="CR64">64</xref>). However, in comparison to L-Dopa dosing in rats, the developed phenylalanine prodrug (Fig. <xref ref-type="fig" rid="Fig2">2W</xref>) did not increase the levels of dopamine in the striatum after i.p. injection (<xref ref-type="bibr" rid="CR64">64</xref>). The L-tryptophan prodrug of benzoic acid (Fig. <xref ref-type="fig" rid="Fig2">2Y</xref>) has been designed based on the three-dimensional (3D) quantitative structure–activity relationship (QSAR) analysis of LAT1 binding of substrates by using classical and topomer comparative molecular field analysis and the data from the <italic>in situ</italic> rat brain perfusion technique (<xref ref-type="bibr" rid="CR53">53</xref>). The prodrug showed the ability to inhibit the brain uptake of L-[<sup>14</sup>C]-leucine using <italic>in situ</italic> brain perfusion in rat (<xref ref-type="bibr" rid="CR53">53</xref>).</p>
<p id="Par58">The developed perforin inhibitor ester- (Fig. <xref ref-type="fig" rid="Fig3">3A</xref>) and amide-based (Fig. <xref ref-type="fig" rid="Fig3">3B</xref>) derivatives inhibited L-[<sup>14</sup>C]-leucine brain uptake after the <italic>in situ</italic> mouse brain perfusion (<xref ref-type="bibr" rid="CR71">71</xref>). However, their brain uptake was not inhibited after co-perfusion with LAT1 substrate, L-tryptophan, suggesting utilization of transporter(s) other than LAT1. Interestingly, the cellular uptake of both derivatives was doubled by L-tryptophan in MCF-7 cells, providing additional evidence that the transporters other than LAT1 can be involved in their uptake (<xref ref-type="bibr" rid="CR72">72</xref>). The cell uptake kinetics analysis, performed in MCF-7 cells, revealed involvement of two transporters, i.e. high-affinity low-capacity transporter and low-affinity high-capacity transporter (<xref ref-type="bibr" rid="CR72">72</xref>). Interestingly, the uptake of ester-based prodrug of perforin inhibitor (Fig. <xref ref-type="fig" rid="Fig3">3A</xref>) into primary mouse neurons and immortalized microglia was reduced by approximately 25% by LAT1 inhibitor (KMH-233), while the uptake of this compound to mouse astrocytes decreased by around 70% by LAT1 inhibitor (<xref ref-type="bibr" rid="CR74">74</xref>). Both prodrugs reached the brain after a single dose administered by i.p. injection in mice, while administration of the parent drugs did not result in BBB permeation. In addition, the parent drug was detected in the brain only after dosing with the ester-based prodrug (Fig. <xref ref-type="fig" rid="Fig3">3A</xref>) (<xref ref-type="bibr" rid="CR71">71</xref>). Interestingly, the released parent drug was not detected in liver after a single dose i.p. injection of both prodrugs in mice. The ratio of liver AUC to plasma AUC for prodrugs (Fig. <xref ref-type="fig" rid="Fig3">3A, B</xref>) was significantly lower than that for parent drugs after a single dose i.p. injection in mice (<xref ref-type="bibr" rid="CR71">71</xref>).</p>
<p id="Par59">Recently, the structure-pharmacokinetics relationship of five derivatives of ketoprofen (Fig. <xref ref-type="fig" rid="Fig2">2N</xref>, Fig. <xref ref-type="fig" rid="Fig3">3C, D, E, F</xref>) designed to utilize LAT1 was investigated (<xref ref-type="bibr" rid="CR57">57</xref>). The study confirmed the previous findings that the aromaticity presented in the prodrug’s promoiety plays a significant role in affinity to LAT1 and its utilization for cellular uptake of prodrugs. Thus, phenylalanine derivatives (Fig. <xref ref-type="fig" rid="Fig3">3C, D, E</xref>) but not derivatives with aliphatic promoieties, (Fig. <xref ref-type="fig" rid="Fig2">2N</xref>, Fig. <xref ref-type="fig" rid="Fig3">3F</xref>) significantly inhibited the uptake of L-[<sup>14</sup>C]-leucine in human retinal pigmented epithelial cells ARPE-19 cells. However, the uptake of all five derivatives was significantly inhibited by the LAT1 inhibitor, KMH-233 (<xref ref-type="bibr" rid="CR66">66</xref>). Importantly, while all derivatives showed an ability to cross the mouse BBB according to <italic>in situ</italic> brain perfusion and could detected after a single i.p. injection of compounds in mice, the released parent drug was quantified in the brain only after administration of phenylalanine derivatives (Fig. <xref ref-type="fig" rid="Fig3">3C, D</xref>). The ratios of AUCs for the brain to plasma for unbound released ketoprofen from <italic>meta-</italic> and <italic>para-</italic>substituted phenylalanine derivatives (0.13 and 0.35, respectively) were significantly higher as compared to ketoprofen dosing (0.01) (<xref ref-type="bibr" rid="CR66">66</xref>). In addition, five times higher ratios of AUCs for the brain to liver of ketoprofen released from these prodrugs were estimated as compared to ketoprofen i.p. dosing in mice (<xref ref-type="bibr" rid="CR66">66</xref>). Thus, the study revealed that <italic>meta-</italic> or <italic>para-</italic>conjugation of phenylalanine directly to the parent drug molecule such as ketoprofen is an important structural feature which can provide targeted brain delivery of ketoprofen with reduced systemic exposure to the released parent drug. Importantly, an intra-brain distribution study of <italic>meta-</italic>conjugated phenylalanine prodrug of ketoprofen (Fig. <xref ref-type="fig" rid="Fig3">3C</xref>) using the brain slice method in mice and rats revealed a predominantly LAT1-mediated delivery of this prodrug to the intracellular compartment of the brain parenchyma in mice and rats (<xref ref-type="bibr" rid="CR73">73</xref>). Thus, these findings suggest that in addition to reduced peripheral exposure to released parent drug, this prodrug enhanced the delivery of ketoprofen to the intracellular compartment of the brain parenchyma where the target, cyclooxygenase, is located. In addition, it has been demonstrated for the first time that the intra-brain distribution of LAT1-utilizing prodrug of ketoprofen (Fig. <xref ref-type="fig" rid="Fig3">3C</xref>) did not affect the transporter function such as amino acid transport and protein expression as shown in brain slices of mice and rats (<xref ref-type="bibr" rid="CR73">73</xref>). In addition, Huttunen et al. (2019) reported that this prodrug accumulated in primary neurons and astrocytes, as well as in immortalized microglia <italic>in vitro</italic> (<xref ref-type="bibr" rid="CR74">74</xref>). However, the role of LAT1 in the uptake of the prodrug to these cells was not confirmed. Moreover, the concentrations of the prodrug used in the study were higher than its <italic>Km</italic> value determined in the uptake studies in ARPE-19 cells (<xref ref-type="bibr" rid="CR57">57</xref>) suggesting that at these concentrations the prodrug can utilize other transporter(s). Importantly, the findings of this structure-pharmacokinetic relationship analysis (<xref ref-type="bibr" rid="CR57">57</xref>) and 3D QSAR (<xref ref-type="bibr" rid="CR53">53</xref>) were confirmed in the study of derivatives developed to improve brain delivery of natural phenolic compound ferulic acid. The results revealed that the amide-based <italic>meta-</italic>conjugated phenylalanine derivatives of this agent (Fig. <xref ref-type="fig" rid="Fig2">2G, H</xref>) were efficiently bound to LAT1 and utilized the transporter for cellular uptake as well as permeating into the mouse brain after i.p. injection (<xref ref-type="bibr" rid="CR56">56</xref>). However, the delivery of ferulic acid has not been improved after the dosing of these derivatives, as the AUC and C<sub>max</sub> of the released ferulic acid in the brain after a single dose i.p. injection of <italic>meta</italic>-substituted phenylalanine derivative was more than three times lower than after parent drug administration (<xref ref-type="bibr" rid="CR56">56</xref>).</p>
<p id="Par60">In the studies of Puris et al. (2019) (<xref ref-type="bibr" rid="CR56">56</xref>) and Huttunen et al. (2018) (<xref ref-type="bibr" rid="CR75">75</xref>), the change of the linker from amide (Fig. <xref ref-type="fig" rid="Fig3">3C,G</xref>) to ester bond between the promoiety (Fig. <xref ref-type="fig" rid="Fig3">3I, J</xref>) and parent drugs (ferulic acid and ketoprofen, respectively), resulted in a loss of LAT1 substrate specificity <italic>in vitro</italic>. Therefore, the design of prodrugs/derivatives with either ester-or amide-linker needs to be justified for each parent drug on a case by case basis.</p>
<p id="Par61">All in all, the results of these studies illustrate that LAT1 natural substrates might serve as a promising template for improving the delivery of drugs into the brain. However, the review revealed that only a few studies have demonstrated LAT1-mediated BBB permeation (<xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR64">64</xref>), i.e. for most of the compounds, it is only the affinity to LAT1 which has been investigated, either using <italic>in situ</italic> brain perfusion or <italic>in vitro</italic> cellular uptake inhibition experiments with LAT1 substrates. In addition, information about the intra-brain distribution has been provided only for two compounds (Fig. <xref ref-type="fig" rid="Fig2">2H</xref>, Fig. <xref ref-type="fig" rid="Fig3">3C</xref>). Moreover, there is a lack of the knowledge about the distribution to other tissues and therefore it is difficult to evaluate the brain targeting via LAT1, as only two studies (<xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR71">71</xref>) measured the distribution of (pro) drugs to liver and compared it to the brain distribution. Therefore, future studies should focus on more complex investigations of the delivery via LAT1 across the BBB, the cellular barrier of the brain parenchyma and other organs.</p>
</sec>
</sec>
<sec id="Sec8">
<title>Ocular delivery via LAT1</title>
<p id="Par62">In conjunction with the improvement of the transport across the BBB, LAT1-mediated delivery has been used to circumvent poor permeability across the BRB. The LAT1 is expressed in the retina, where it is responsible for the exchange of amino acids (<xref ref-type="bibr" rid="CR76">76</xref>,<xref ref-type="bibr" rid="CR77">77</xref>) offering the opportunity for LAT1-mediated delivery of the drugs. Thus, several amino acid ester prodrugs of acyclovir have been developed, and the permeation of L-serine derivative of acyclovir (Fig. <xref ref-type="fig" rid="Fig3">3K</xref>) across cornea was inhibited by arginine and BCH, pointing to the involvement of cationic amino acid transporter 1 and LAT1 in its transport (<xref ref-type="bibr" rid="CR78">78</xref>,<xref ref-type="bibr" rid="CR79">79</xref>). Moreover, the derivative of acyclovir led to higher concentrations of acyclovir being released in the aqueous humour as compared to the parent drug in a study using a combination of the topical well infusion and aqueous humour microdialysis techniques in rabbits (<xref ref-type="bibr" rid="CR79">79</xref>). Akanuma et al. (2018) demonstrated that [<sup>3</sup>H]-gabapentin utilized LAT1 for passage across the BRB in rats after carotid artery injection as well as cellular uptake <italic>in vitro</italic> in the models of the inner (TR-iBRB2 cells) and outer BRB (rat retinal pigment epithelial RPE-J cells), since the uptake of the compound was inhibited by LAT1 substrates (<xref ref-type="bibr" rid="CR80">80</xref>). These studies hold promise that LAT1-mediated (pro) drug delivery could be used not only for the brain targeting, but also for the passage of the compounds across other LAT1 expressing barrier tissues such as BRB. However, additional studies will be required to investigate the efficiency of this strategy for the BRB delivery.</p>
</sec>
<sec id="Sec9">
<title>Delivery of anticancer agents</title>
<p id="Par63">Due to the significant up-regulation of LAT1 expression in several human tumors, LAT1 has been an attractive transporter for targeted delivery of amino acid-derived anticancer drugs and prodrugs as well as positron emission tomography (PET) probes for cancer diagnosis. In this chapter, we will summarize the studies focusing on the development of LAT1-utilizing compounds targeting cancer cells.</p>
<sec id="Sec10">
<title>Delivery of anticancer (pro)drugs</title>
<p id="Par64">LAT1 has been shown to be involved in transport of anticancer drugs such as melphalan (Fig. <xref ref-type="fig" rid="Fig4">4A</xref>) and acivicin (Fig. <xref ref-type="fig" rid="Fig4">4B</xref>). The L-phenylalanine prodrug melphalan (Fig. <xref ref-type="fig" rid="Fig4">4A</xref>), a widely used anticancer drug for the treatment of ovarian cancer and multiple myeloma, inhibited the uptake of L-leucine into human MDA-MB-231 breast cancer cells (<xref ref-type="bibr" rid="CR81">81</xref>), T24 human bladder carcinoma cells (<xref ref-type="bibr" rid="CR82">82</xref>) and in hLAT1 expressing <italic>Xenopus</italic> oocytes (<xref ref-type="bibr" rid="CR16">16</xref>) providing evidence of binding to LAT1. Melphalan at therapeutic doses reduced the total number of cells and the live-to-dead cell ratio in two esophageal adenocarcinoma cell lines, i.e. Bic-1 and Seg-1, and in the SV-40-immortalized esophageal squamous cell line, Het-1A (<xref ref-type="bibr" rid="CR83">83</xref>). The sensitivity to the effects of melphalan decreased after simultaneous incubation with the competitive LAT1 inhibitor BCH, demonstrating LAT1-mediated cellular uptake of the drug in the above-mentioned cell lines. Moreover, the transporter mediated passage of melphalan across the rat BBB after <italic>in situ</italic> brain perfusion (<xref ref-type="bibr" rid="CR84">84</xref>). As melphalan is used for anti-cancer chemotherapy in patients with retinoblastoma, Hosoya et al. (2008) investigated the LAT1 binding of melphalan and other synthetic amino acid-conjugated mustards in LAT1 expressing conditionally immortalized rat retinal endothelial TR-iBRB2 cells (<xref ref-type="bibr" rid="CR85">85</xref>). The study showed that melphalan inhibited the uptake of [<sup>3</sup>H]-phenylalanine, evidence in support of its binding to LAT1 (<xref ref-type="bibr" rid="CR85">85</xref>). Furthermore, Hosoya et al. (2008) demonstrated that while lysine-mustard (Fig. <xref ref-type="fig" rid="Fig4">4C</xref>) and aromatic amino acid-mustards (Fig. <xref ref-type="fig" rid="Fig4">4D, E</xref>) significantly inhibited [<sup>3</sup>H]-phenylalanine uptake in TR-iBRB2 cells, aliphatic amino acid-mustards, such as alanine-mustard (Fig. <xref ref-type="fig" rid="Fig4">4F</xref>) and ornithine-mustard (Fig. <xref ref-type="fig" rid="Fig4">4G</xref>), did not bind to LAT1 (<xref ref-type="bibr" rid="CR85">85</xref>). Interestingly, the analogue of melphalan, a nitrogen mustard amino acid D,L-2-amino-7-bis[(2-chloroethyl)amino]-l,2,3,4-tetrahydro-2-naphthoic acid (D,L-NAM) (Fig. <xref ref-type="fig" rid="Fig4">4H</xref>), utilized LAT1 for cellular uptake into murine L1210 lymphocytic leukaemia cells (<xref ref-type="bibr" rid="CR86">86</xref>) and exhibited 50-times higher affinity for LAT1 at the rat BBB than melphalan after <italic>in situ</italic> brain perfusion (<xref ref-type="bibr" rid="CR87">87</xref>). As a result, the BBB penetration of D,L-NAM in rats was more than 20 times greater than that of melphalan after <italic>in situ</italic> brain perfusion (<xref ref-type="bibr" rid="CR87">87</xref>). In another study, several isomers (C-6 and C-8) of D,L-NAM (C-7 isomer) were synthetized in order to improve the affinity of the agent (<xref ref-type="bibr" rid="CR88">88</xref>). However, when investigated using <italic>in situ</italic> rat brain perfusion, it was found that all compounds had lower affinity to LAT1 as compared to D,L-NAM.<fig id="Fig4"><label>Fig. 4</label><caption><p>Chemical structures, molecular weight (MW) and logP of amino acid anticancer drugs and derivatives designed to utilize LAT1: melphalan (<bold>a</bold>), acivicin (<bold>b</bold>), derivatives of mustards (<bold>c</bold>-<bold>g</bold>), D,L-2-amino-7-bis[(2-chloroethyl)amino]-l,2,3,4-tetrahydro-2-naphthoic acid (<bold>h</bold>), derivative of gemcitabine (<bold>i</bold>), derivative of doxorubicin (<bold>j</bold>) derivative of methotrexate (<bold>k</bold>), 3CDIT (<bold>l</bold>). The values of logP were calculated using Marvin Sketch version 15.8.31 (ChemAxon, Budapest, Hungary).</p></caption><graphic id="MO4" xlink:href="11095_2020_2826_Fig4_HTML"></graphic></fig></p>
<p id="Par65">LAT1 is involved in transport of another anticancer drug, acivicin (Fig. <xref ref-type="fig" rid="Fig4">4B</xref>), as demonstrated in a <italic>trans</italic>-stimulation assay of L-leucine efflux in human embryonic kidney HEK-LAT1 cells (<xref ref-type="bibr" rid="CR23">23</xref>). However, the drug has failed due to unacceptable CNS toxicity caused by the high distribution of the compound to the brain. In cats, the toxic CNS effects could be reduced after concomitant administration of acivicin and a mixture of four large neutral amino acids or Aminosyn (mixture of 16 amino acids), i.e. evidence for the involvement of LAT1 in the brain distribution of the drug (<xref ref-type="bibr" rid="CR89">89</xref>).</p>
<p id="Par66">Another attempt to apply an LAT1-mediated delivery approach for cancer targeting has been conducted by Hong et al. (2018) who developed a threonine-derivative of gemcitabine (Fig. <xref ref-type="fig" rid="Fig5">5I</xref>) (<xref ref-type="bibr" rid="CR90">90</xref>). The compound evoked a greater cytotoxic effect in LAT1-overexpressing human pancreatic cancer cells, BxPC-3 and MIAPaCa-2, as compared to the parent drug (<xref ref-type="bibr" rid="CR89">89</xref>). However, no evidence of LAT1-utilization by the derivative was reported; this compound does not fulfil the structural requirements of a LAT1 substrate. In another study, an aspartate derivative of doxorubicin (Fig. <xref ref-type="fig" rid="Fig4">4J</xref>) inhibited the uptake of L-[<sup>3</sup>H]-leucine in the S2-LAT1 transgene cell line demonstrating binding to the transporter (<xref ref-type="bibr" rid="CR91">91</xref>). Importantly, in human liver cancer HepG2 (LAT1-positive) tumor-bearing mice, this derivative exerted a significantly stronger inhibition of tumour growth as compared to doxorubicin treatment (<xref ref-type="bibr" rid="CR91">91</xref>). Singh et al. (2016) applied the LAT1-mediated prodrug approach to improve delivery of methotrexate to a brain tumour by conjugating the drug to lysine (Fig. <xref ref-type="fig" rid="Fig4">4K</xref>) via a carboxylic acid group (<xref ref-type="bibr" rid="CR92">92</xref>). The compound demonstrated a four times greater distribution of released methotrexate between brain and plasma in comparison to that encountered after the i.v. administration of the parent drug in mice (<xref ref-type="bibr" rid="CR92">92</xref>). However, the involvement of LAT1 in delivery of the conjugate was not investigated. Moreover, a biodistribution study in mice with i.v. administration of both the stable radiolabelled parent drug and conjugate showed that both compounds were widely distributed to many tissues including liver, spleen, lung and kidney (<xref ref-type="bibr" rid="CR92">92</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>Chemical structures, molecular weight (MW) and logP of amino acid-based PET tracers L-[<sup>11</sup>C]-methyl-methionine (A), <italic>O</italic>-(2-[<sup>18</sup>F]-fluoroethyl)-L-tyrosine (B), 6-[<sup>18</sup>F]-fluoro-L-3,4-dihydroxy-phenylalanine (C), L-3-[<sup>18</sup>F]-fluoro-α-methyl tyrosine (D), (<italic>S</italic>)-2-amino-3-[3-(2-[<sup>18</sup>F]-fluoroethoxy)-4-iodophenyl]-2-methylpropanoic acid (E) as well as <italic>p</italic>-borono-phenylalanine (F). The values of logP were calculated using Marvin Sketch version 15.8.31 (ChemAxon, Budapest, Hungary).</p></caption><graphic id="MO5" xlink:href="11095_2020_2826_Fig5_HTML"></graphic></fig></p>
<p id="Par67">There are several studies describing the potential of LAT1 utilization for enhanced delivery of nanoparticles and liposomes into cancer cells. Thus, An et al. (2016) intercalated doxorubicin into the adenosine-5′-triphosphate (ATP) responsive DNA scaffold, which was subsequently condensed and protected with a glutathione responsive polymer pOEI and functionalized with the LAT1 substrate 3CDIT (Fig. <xref ref-type="fig" rid="Fig4">4L</xref>) responsible for targeting the drug to tumour cells (<xref ref-type="bibr" rid="CR93">93</xref>). The 3CDIT-targeting pOEI/doxorubicin/ATP aptamer nanoparticles demonstrated an outstanding accumulation in human-derived malignant glioma cells U87. Moreover, there was enhanced accumulation and doxorubicin release at the glioma tumour site as well as an improved antitumor therapeutic effect after i.v. injection of fluorescent-labelled nanoparticles in glioma model nude mice without any signs of systemic toxicity (<xref ref-type="bibr" rid="CR93">93</xref>). In another study, Bhunia et al. (2017) developed LAT1 a selective liposomal drug carrier prepared from a novel L-Dopa functionalized amphiphile (Amphi-Dopa) (<xref ref-type="bibr" rid="CR94">94</xref>). In the biodistribution study, the NIR-dye labelled liposomes of Amphi-Dopa were detected in the brain, liver and spleen at 4 h after i.v. administration but predominantly in the brain at 24 h in glioblastoma-bearing mice (<xref ref-type="bibr" rid="CR94">94</xref>). The i.v. administration of the liposomes encapsulated with WP-1066, a potent signal transducer and activator of transcription 3 inhibitor, increased the overall survivability of mice bearing orthotopically established mouse glioblastoma dramatically (by ∼60%) as compared to that for the untreated mouse group (<xref ref-type="bibr" rid="CR94">94</xref>).</p>
<p id="Par68">Conjugation of liposomes and nanoparticles to glutamate has been used for improving the delivery of paclitaxel (<xref ref-type="bibr" rid="CR95">95</xref>) and docetaxel (<xref ref-type="bibr" rid="CR96">96</xref>) to cancer cells. The uptake of the liposomes in LAT1-expressing glioma cells was inhibited by leucine and phenylalanine only by 20–25% (<xref ref-type="bibr" rid="CR96">96</xref>). The uptake of the nanoparticles was higher in LAT1-overexpressing cells (human cervix epitheloid carcinoma HeLa cells and MCF-7 cells) when compared to the situation in a LAT1 non-expressing cell line from Mouse Swiss NIH embryo NIH 3 T3 cells (<xref ref-type="bibr" rid="CR95">95</xref>). Although based on these findings, the authors suggested LAT1-mediated delivery of the developed liposomes and nanoparticles, there is insufficient evidence for the involvement of LAT1 in the delivery of glutamine conjugates. In another study, the conjugation of L- and D-Dopa conjugated anisotropic gold nanoparticles increased the accumulation in several breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-468, and MDA-MB-453) as compared to non-targeted nanoparticles conjugated with dopamine and 4-ethylcatechol (<xref ref-type="bibr" rid="CR97">97</xref>). Moreover, the authors demonstrated LAT1-mediated accumulation of the L-Dopa functionalized anisotropic gold nanoparticles in MCF-7 cells, and the uptake was significantly inhibited by phenylalanine (<xref ref-type="bibr" rid="CR97">97</xref>).</p>
</sec>
<sec id="Sec11">
<title>Delivery of PET probes for cancer imaging</title>
<p id="Par69">The knowledge of LAT1 overexpression in tumours and its substrate specificity has been exploited in the development of radiolabelled probes, transporter substrates, used in cancer diagnostics. The labelling of [<sup>18</sup>F] or [<sup>11</sup>C] in the LAT1 substrate structure allows PET imaging of accumulated compounds in cancer foci after their administration. Thus, several amino acids based probes have been developed including (<italic>S</italic>)-2-amino-3-[3-(2-[<sup>18</sup>F]-fluoroethoxy)-4-iodophenyl]-2-methylpropanoic acid ([<sup>18</sup>F]-FIMP), L-3-[<sup>18</sup>F]-fluoro-α-methyl tyrosine ([<sup>18</sup>F]-FAMT), 6-[<sup>18</sup>F]-fluoro-L-3,4-dihydroxy-phenylalanine ([<sup>18</sup>F]-DOPA), L-[<sup>11</sup>C]-methyl-methionine ([<sup>11</sup>C]-MET) and <italic>O</italic>-(2-[<sup>18</sup>F]-fluoroethyl)-L-tyrosine ([<sup>18</sup>F]-FET). [<sup>11</sup>C]-MET (Fig. <xref ref-type="fig" rid="Fig5">5A</xref>) has been the most commonly used radiolabelled amino acid due to its convenient and rapid synthesis (<xref ref-type="bibr" rid="CR98">98</xref>) and high specificity in tumour detection, delineation and in the differentiation of benign from malignant lesions (<xref ref-type="bibr" rid="CR99">99</xref>). In terms of LAT1-mediated delivery, Okubo et al. (2010) revealed that uptake of [<sup>11</sup>C]-MET in human newly diagnosed gliomas was correlated with the extent of LAT1 expression (<xref ref-type="bibr" rid="CR100">100</xref>). Later, the development of another amino acid-based PET tracer [<sup>18</sup>F]-FET (Fig. <xref ref-type="fig" rid="Fig5">5B</xref>), a tyrosine analogue with a longer half-life of <sup>18</sup>F, meant that it was possible to use this tracer in centres with no access to a cyclotron. The tracer provided information comparable to that obtained with [<sup>11</sup>C]-MET in the diagnostics of gliomas and brain metastases (<xref ref-type="bibr" rid="CR101">101</xref>). Non-labelled FET induced approximately 1% efflux of preinjected phenylalanine in a <italic>trans</italic>-stimulation study in <italic>Xenopus laevis</italic> oocytes expressing h4F2hc-hLAT1 (<xref ref-type="bibr" rid="CR102">102</xref>) indicative of low extracellular affinity to LAT1 or a slow transport rate of FET. In contrast, Habermeier et al. (2015) showed that extracellular FET stimulated the efflux of intracellular L-[<sup>3</sup>H]-leucine in <italic>Xenopus laevis</italic> oocytes expressing human h4F2hc-hLAT1, while preinjected FET to the oocytes did not stimulate L-[<sup>3</sup>H]-leucine influx into the cells, interpreted to mean that FET was an influx, but not an efflux LAT1 substrate (<xref ref-type="bibr" rid="CR103">103</xref>). The discrepancy between the study findings of Lahoutte et al. (2004) and Habermeier et al. (2015) can be explained by the different transport kinetics of LAT1 substrates, phenylalanine and leucine, used in these studies (<xref ref-type="bibr" rid="CR13">13</xref>). In addition, in the study of Habermeier et al. (2015), FET significantly inhibited the uptake of L-[<sup>3</sup>H]-tyrosine in LN229 glioblastoma cells suggesting that it was utilizing LAT1 as it accumulated in the oocytes expressing human h4F2hc-hLAT1, but not in control non-expressing LAT1 oocytes (<xref ref-type="bibr" rid="CR103">103</xref>). The PET tracer [<sup>18</sup>F]-DOPA (Fig. <xref ref-type="fig" rid="Fig5">5C</xref>) has been widely used for research in the field of neuroendocrine tumours and movement disorders; it has been demonstrated an efficacy comparable to [<sup>11</sup>C]-MET for detecting brain tumors (<xref ref-type="bibr" rid="CR104">104</xref>). In another study, the compound exhibited the best performance for the diagnostic of recurrent medullary thyroid carcinoma as compared to [<sup>11</sup>C]-MET, 2-deoxy-2-[<sup>18</sup>F]-fluoro-d-glucose ([<sup>18</sup>F]-FDG), Ga-somatostatin analogues and 3-<italic>O</italic>-methyl-6-[<sup>18</sup>F]-fluoro-DOPA (<xref ref-type="bibr" rid="CR105">105</xref>). The uptake of [<sup>18</sup>F]-DOPA in biopsy samples of patients with newly diagnosed astrocytoma correlated with LAT1 expression (<xref ref-type="bibr" rid="CR106">106</xref>). Tomiyoshi et al. (1997) synthetized an amino acid probe, [<sup>18</sup>F]-FAMT (Fig. <xref ref-type="fig" rid="Fig5">5D</xref>), which significantly inhibited LAT1-mediated uptake of L-[<sup>14</sup>C]-leucine and stimulated the efflux of preloaded L-[<sup>14</sup>C]-leucine indicating binding to LAT1 (<xref ref-type="bibr" rid="CR107">107</xref>). In addition, the compound utilized the transporter for uptake in mouse renal proximal tubule cell line S2 stably expressing hLAT1 (<xref ref-type="bibr" rid="CR108">108</xref>). Moreover, the uptake of [<sup>18</sup>F]-FAMT in the tumour correlated with the LAT1 expression level in patients with non–small-cell lung cancer (<xref ref-type="bibr" rid="CR109">109</xref>) and oral squamous cell carcinoma (<xref ref-type="bibr" rid="CR110">110</xref>). Recently, Nozaki et al. (2019) designed and synthetized a phenylalanine based tracer, [<sup>18</sup>F]-FIMP (Fig. <xref ref-type="fig" rid="Fig5">5E</xref>), which demonstrated greater tumor targeted delivery in the subcutaneous LAT1-positive human glioblastoma xenograft model as compared to [<sup>18</sup>F]-FET, [<sup>11</sup>C]-MET and [<sup>18</sup>F]-FDG (<xref ref-type="bibr" rid="CR111">111</xref>).</p>
</sec>
<sec id="Sec12">
<title>Boron neutron capture therapy</title>
<p id="Par70">Targeting of anticancer agents via LAT1 has been applied for boron neutron capture therapy (BNCT) with the focus on patients suffering from high grade glioma (<xref ref-type="bibr" rid="CR112">112</xref>,<xref ref-type="bibr" rid="CR113">113</xref>). BNCT is a radiotherapy which is based on a nuclear fission reaction that occurs when <sup>10</sup>B is irradiated with low energy thermal neutron beams and high-energy alpha-particles (<sup>4</sup>He<sup>2+</sup>) and recoiling lithium (<sup>7</sup>Li) nuclei (<xref ref-type="bibr" rid="CR114">114</xref>). The efficacy of the BNCT is dependent on <sup>10</sup>B accumulation in cancer tissue, which can be improved via LAT1-mediated delivery. Thus, <italic>p</italic>-borono-phenylalanine (BPA, Fig. <xref ref-type="fig" rid="Fig5">5F</xref>), a boron compound widely used in BNCT, demonstrated higher affinity to LAT1 as compared to LAT2 and ATB<sup>0,+</sup> in <italic>Xenopus laevis</italic> oocytes expressing human h4F2hc-hLAT1 (<xref ref-type="bibr" rid="CR115">115</xref>). However, the authors assumed that at therapeutic doses, the compound would be able to utilize both LAT1 and ATB<sup>0,+</sup> for its uptake into cancer tissue (<xref ref-type="bibr" rid="CR115">115</xref>).</p>
<p id="Par71">Overall, these studies indicate that it should be possible to develop LAT1 selective compounds to be delivered via this transporter to cancer tissue for use in chemotherapy and cancer diagnostics. In this respect, a more systematic investigation of LAT1-mediated delivery and also a deeper understanding distribution of the compounds to healthy tissues are vital for the evaluation of the usefulness of the approach.</p>
</sec>
</sec>
<sec id="Sec13">
<title>Opportunities and limitations of LAT1-mediated drug delivery</title>
<p id="Par72">The LAT1- mediated delivery is a promising approach, which has found applications not only in improving delivery of drugs, but also for diagnostic purposes<bold>.</bold> However, as the present review demonstrated, although a great number of (pro) drugs have been developed to improve targeted delivery via LAT1, only a limited number of LAT1-utilizing agents have entered clinical trials or are currently being used in clinical practice. In addition, only a few studies have demonstrated the utilization of LAT1 for delivery of investigated compounds; most of the studies lack evidence of LAT1-mediated uptake of the (pro) drugs or agents, which complicates the evaluation of the effectiveness of this approach. Furthermore, as there is no standardized procedure(s) for the evaluation of transporter-mediated delivery, the use of different methods (<italic>in vitro</italic>, <italic>in situ</italic> and <italic>in vivo</italic>) in the studies makes it difficult to compare the results such as transport kinetics parameters and distribution to target tissue.</p>
<p id="Par73">There are several limitations of the approach which should be considered during the development of LAT1-utilizing (pro) drugs and agents. First, this delivery method is applicable for small-molecule drugs and not suitable for the delivery of macromolecules. The molecular weight of the summarized pro (drugs) with reported affinity to LAT1 and transporter-mediated uptake ranged between 148.21–513.56 g/mol. In the case of LAT1-mediated delivery of nanoparticles and liposomes, it seems evident that LAT1 plays a role in directing the nano-carrier to the cells expressing the transporter through the binding to LAT1 rather than delivering the nanoparticle via the transporter. Second, as discussed above (chapter “Brain delivery of CNS-acting drugs”), the LAT1-mediated (pro) drug approach provides predominant intracellular distribution of the substrates and therefore can benefit the delivery of the drugs with intracellular, but not extracellular targets. In addition, the affinity of (pro) drugs to LAT1 should be sufficient to be able to compete with natural substrates for LAT1 binding, but not enough to interfere with their homeostasis in the case of the non-cancerous tissue targeting. The review demonstrated that only limited information regarding the effect of LAT1-utilizing (pro) drugs on amino acid homeostasis is available; clearly future studies should address this issue.</p>
<p id="Par74">Finally, one should remember that absolute targeting via LAT1 to a particular organ cannot be achieved due to the expression of LAT1 in several tissues and its overlapping substrate specificity with other transporters. The present review revealed that only a few studies have addressed the issue of targeting via LAT1 and investigated the systemic distribution of the compounds. Therefore, future research should focus on investigating the distribution of LAT1-utilizing (pro) drugs and agents to other tissues, in particular for cancer targeting. Thus, the selection of LAT1-mediated drug delivery should be carefully considered for each compound taking into account the advantages of the approach and its limitations.</p>
</sec>
<sec id="Sec14">
<title>Conclusions</title>
<p id="Par75">LAT1-mediated drug delivery is a promising approach, which has demonstrated its effectiveness for the brain- and cancer-targeted delivery of several agents, and it might be potentially used for delivery to other LAT-expressing tissues. In addition, several promising compounds have been developed and demonstrated the ability to bind to LAT1 and reach the target tissue in animal models. However, this review revealed that there is a lack of systematic knowledge of the efficiency of LAT1-mediated delivery <italic>in vivo</italic>, the distribution of compounds to non-target tissues, the proof of pharmacodynamic efficacy in disease models and translation of the data to humans. Therefore, further studies will be required to shed light on these issues if there is to be effective utilization of this approach in the targeted delivery of therapeutic compounds.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>
<italic>APP</italic>
</term>
<def>
<p id="Par2">Amyloid precursor protein</p>
</def>
</def-item>
<def-item>
<term>ATB<sup>0,+</sup></term>
<def>
<p id="Par3">b(0,+)-Type amino acid transporter</p>
</def>
</def-item>
<def-item>
<term>ATP</term>
<def>
<p id="Par4">Adenosine triphosphate</p>
</def>
</def-item>
<def-item>
<term>AUC</term>
<def>
<p id="Par5">Area under the total plasma or tissue concentration–time curve</p>
</def>
</def-item>
<def-item>
<term>BBB</term>
<def>
<p id="Par6">Blood-brain barrier</p>
</def>
</def-item>
<def-item>
<term>BCH</term>
<def>
<p id="Par7">2-amino-2-norbornanecarboxylic acid</p>
</def>
</def-item>
<def-item>
<term>BNCT</term>
<def>
<p id="Par8">Boron neutron capture therapy</p>
</def>
</def-item>
<def-item>
<term>BPA</term>
<def>
<p id="Par9"><italic>p</italic>-borono-phenylalanine</p>
</def>
</def-item>
<def-item>
<term>BRB</term>
<def>
<p id="Par10">Blood-retinal barrier</p>
</def>
</def-item>
<def-item>
<term>C<sub>max</sub></term>
<def>
<p id="Par11">Maximum total concentration of the drug achieved in the plasma or tissue</p>
</def>
</def-item>
<def-item>
<term>CNS</term>
<def>
<p id="Par12">Central nervous system</p>
</def>
</def-item>
<def-item>
<term>D,L-NAM</term>
<def>
<p id="Par13">D,L-2-amino-7-bis[(2-chloroethyl)amino]-l,2,3,4-tetrahydro-2-naphthoic acid</p>
</def>
</def-item>
<def-item>
<term>DNA</term>
<def>
<p id="Par14">Deoxyribonucleic acid</p>
</def>
</def-item>
<def-item>
<term>IC<sub>50</sub></term>
<def>
<p id="Par15">Concentration of an inhibitor at which the response (or binding) is reduced by half</p>
</def>
</def-item>
<def-item>
<term>IL</term>
<def>
<p id="Par16">Interleukins</p>
</def>
</def-item>
<def-item>
<term>i.p.</term>
<def>
<p id="Par17">Intraperitoneal route of administration</p>
</def>
</def-item>
<def-item>
<term>i.v.</term>
<def>
<p id="Par18">Intravenous route of administration</p>
</def>
</def-item>
<def-item>
<term>
<italic>K</italic>
<sub>m</sub>
</term>
<def>
<p id="Par19">Constant of Michaelis-Menten kinetics</p>
</def>
</def-item>
<def-item>
<term>LAT</term>
<def>
<p id="Par20">L-type amino acid transporter</p>
</def>
</def-item>
<def-item>
<term>LPS</term>
<def>
<p id="Par21">Lipopolysaccharide</p>
</def>
</def-item>
<def-item>
<term>mRNA</term>
<def>
<p id="Par22">Messenger ribonucleic acid</p>
</def>
</def-item>
<def-item>
<term>PET</term>
<def>
<p id="Par23">Positron emission tomography</p>
</def>
</def-item>
<def-item>
<term>
<italic>PSEN1</italic>
</term>
<def>
<p id="Par24">Presenilin 1</p>
</def>
</def-item>
<def-item>
<term>QSAR </term>
<def>
<p id="Par25">Quantitative structure-activity relationship</p>
</def>
</def-item>
<def-item>
<term>SLC</term>
<def>
<p id="Par26">Solute carrier transporters</p>
</def>
</def-item>
<def-item>
<term>SV-40</term>
<def>
<p id="Par27">Simian virus 40</p>
</def>
</def-item>
<def-item>
<term>
<italic>V</italic>
<sub>
<italic>max</italic>
</sub>
</term>
<def>
<p id="Par28">Maximal transport rate</p>
</def>
</def-item>
<def-item>
<term>3D</term>
<def>
<p id="Par29">Three-dimensional space</p>
</def>
</def-item>
<def-item>
<term>[<sup>11</sup>C]-MET</term>
<def>
<p id="Par30">L-[<sup>11</sup>C]-methyl-methionine</p>
</def>
</def-item>
<def-item>
<term>[<sup>18</sup>F]-DOPA</term>
<def>
<p id="Par31">6-[<sup>18</sup>F]-fluoro-L-3,4-dihydroxy-phenylalanine</p>
</def>
</def-item>
<def-item>
<term>[<sup>18</sup>F]-FAMT</term>
<def>
<p id="Par32">L-3-[<sup>18</sup>F]-fluoro-α-methyl tyrosine</p>
</def>
</def-item>
<def-item>
<term>[<sup>18</sup>F]-FET</term>
<def>
<p id="Par33"><italic>O</italic>-(2-[<sup>18</sup>F]-fluoroethyl)-L-tyrosine</p>
</def>
</def-item>
<def-item>
<term>[<sup>18</sup>F]-FIMP</term>
<def>
<p id="Par34">(<italic>S</italic>)-2-amino-3-[3-(2-[<sup>18</sup>F]-fluoroethoxy)-4-iodophenyl]-2-methylpropanoic acid</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn>
<p>
<bold>Publisher’s Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>ACKNOWLEDGMENTS AND DISCLOSURES</title>
<p>The authors thank Dr. Ewen MacDonald for language editing. The study was supported by the Academy of Finland (K.M.H., grant numbers 294227 and 307057), Finnish Cultural Foundation (E.P.), Alfred Kordelin Foundation (E.P.) and the University of Eastern Finland Doctoral School.</p>
</ack>
<notes notes-type="funding-information">
<title>Funding Information</title>
<p>Open access funding provided by University of Eastern Finland (UEF) including Kuopio University Hospital.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Faix</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Schnitzer</surname>
<given-names>JE</given-names>
</name>
</person-group>
<article-title>Overcoming key biological barriers to cancer drug delivery and efficacy</article-title>
<source/>J Control Release
          <year>2017</year>
<volume>267</volume>
<fpage>15</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">28917530</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Drug targeting. Breaking down barriers</article-title>
<source/>Science.
          <year>2002</year>
<volume>297</volume>
<issue>5584</issue>
<fpage>1116</fpage>
<lpage>1118</lpage>
<pub-id pub-id-type="pmid">12183610</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pardridge</surname>
<given-names>WM</given-names>
</name>
</person-group>
<article-title>The blood-brain barrier: bottleneck in brain drug development</article-title>
<source/>NeuroRx.
          <year>2005</year>
<volume>2</volume>
<issue>1</issue>
<fpage>3</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">15717053</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutera</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>De Caro</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Giannola</surname>
<given-names>LI</given-names>
</name>
</person-group>
<article-title>Small endogenous molecules as moiety to improve targeting of CNS drugs</article-title>
<source/>Expert Opin Drug Deliv
          <year>2017</year>
<volume>14</volume>
<issue>1</issue>
<fpage>93</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="pmid">27367188</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldenberg</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Begleiter</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro</article-title>
<source/>J Biol Chem
          <year>1979</year>
<volume>254</volume>
<issue>4</issue>
<fpage>1057</fpage>
<lpage>1064</lpage>
<pub-id pub-id-type="pmid">762115</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kageyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matsuo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Takakura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hashida</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Naito</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tsuruo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Minato</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shimohama</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier</article-title>
<source/>Brain Res
          <year>2000</year>
<volume>879</volume>
<issue>1–2</issue>
<fpage>115</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="pmid">11011012</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oxender</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>HN</given-names>
</name>
</person-group>
<article-title>Evidence for two types of mediation of neutral and amino-acid transport in Ehrlich cells</article-title>
<source/>Nature.
          <year>1963</year>
<volume>197</volume>
<fpage>765</fpage>
<lpage>767</lpage>
<pub-id pub-id-type="pmid">13940861</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christensen</surname>
<given-names>HN</given-names>
</name>
</person-group>
<article-title>Role of amino acid transport and countertransport in nutrition and metabolism</article-title>
<source/>Physiol Rev
          <year>1990</year>
<volume>70</volume>
<issue>1</issue>
<fpage>43</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="pmid">2404290</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Segawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Miyamoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Uchino</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98)</article-title>
<source/>J Biol Chem
          <year>1998</year>
<volume>273</volume>
<issue>37</issue>
<fpage>23629</fpage>
<lpage>23632</lpage>
<pub-id pub-id-type="pmid">9726963</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verrey</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jack</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Paulsen</surname>
<given-names>IT</given-names>
</name>
<name>
<surname>Saier</surname>
<given-names>MH</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Pfeiffer</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>New glycoprotein-associated amino acid transporters</article-title>
<source/>J Membr Biol
          <year>1999</year>
<volume>172</volume>
<issue>3</issue>
<fpage>181</fpage>
<lpage>192</lpage>
<pub-id pub-id-type="pmid">10568788</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verrey</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Meier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rossier</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>LC</given-names>
</name>
</person-group>
<article-title>Glycoprotein-associated amino acid exchangers: broadening the range of transport specificity</article-title>
<source/>Pflugers Arch
          <year>2000</year>
<volume>440</volume>
<issue>4</issue>
<fpage>503</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="pmid">10958334</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex</article-title>
<source/>Nature.
          <year>2019</year>
<volume>568</volume>
<issue>7750</issue>
<fpage>127</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="pmid">30867591</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ristic</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Klauser</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Verrey</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Activation of system L heterodimeric amino acid exchangers by intracellular substrates</article-title>
<source/>EMBO J
          <year>2002</year>
<volume>21</volume>
<issue>4</issue>
<fpage>580</fpage>
<lpage>589</lpage>
<pub-id pub-id-type="pmid">11847106</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scalise</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Galluccio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Console</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pochini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Indiveri</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>The human SLC7A5 (LAT1): the intriguing Histidine/large neutral amino acid transporter and its relevance to human health</article-title>
<source/>Front Chem
          <year>2018</year>
<volume>6</volume>
<fpage>243</fpage>
<pub-id pub-id-type="pmid">29988369</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mastroberardino</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Spindler</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pfeiffer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Skelly</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Loffing</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shoemaker</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Verrey</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family</article-title>
<source/>Nature.
          <year>1998</year>
<volume>395</volume>
<issue>6699</issue>
<fpage>288</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="pmid">9751058</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yanagida</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chairoungdua</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Segawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nii</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cha</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Matsuo</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fukushima</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fukasawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tani</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Taketani</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Uchino</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Inatomi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Okayasu</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Miyamoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Goya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines</article-title>
<source/>Biochim Biophys Acta
          <year>2001</year>
<volume>1514</volume>
<issue>2</issue>
<fpage>291</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="pmid">11557028</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Kane</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Vina</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hawkins</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Na+ −dependent neutral amino acid transporters a, ASC, and N of the blood-brain barrier: mechanisms for neutral amino acid removal</article-title>
<source/>Am J Physiol Endocrinol Metab
          <year>2004</year>
<volume>287</volume>
<issue>4</issue>
<fpage>E622</fpage>
<lpage>E629</lpage>
<pub-id pub-id-type="pmid">15165996</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friesema</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Docter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Moerings</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Verrey</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Krenning</surname>
<given-names>EP</given-names>
</name>
<name>
<surname>Hennemann</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Visser</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Thyroid hormone transport by the heterodimeric human system L amino acid transporter</article-title>
<source/>Endocrinology.
          <year>2001</year>
<volume>142</volume>
<issue>10</issue>
<fpage>4339</fpage>
<lpage>4348</lpage>
<pub-id pub-id-type="pmid">11564694</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics</article-title>
<source/>Expert Opin Ther Targets
          <year>2015</year>
<volume>19</volume>
<issue>10</issue>
<fpage>1319</fpage>
<lpage>1337</lpage>
<pub-id pub-id-type="pmid">25968633</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kandasamy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gyimesi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hediger</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Amino acid transporters revisited: new views in health and disease</article-title>
<source/>Trends Biochem Sci
          <year>2018</year>
<volume>43</volume>
<issue>10</issue>
<fpage>752</fpage>
<lpage>789</lpage>
<pub-id pub-id-type="pmid">30177408</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<mixed-citation publication-type="other">Singh N, Ecker GF. Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1. Int J Mol Sci. 2018;19(5).</mixed-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Villoutreix</surname>
<given-names>BO</given-names>
</name>
<name>
<surname>Ecker</surname>
<given-names>GF</given-names>
</name>
</person-group>
<article-title>Rigorous sampling of docking poses unveils binding hypothesis for the halogenated ligands of L-type amino acid transporter 1 (LAT1)</article-title>
<source/>Sci Rep
          <year>2019</year>
<volume>9</volume>
<issue>1</issue>
<fpage>15061</fpage>
<pub-id pub-id-type="pmid">31636293</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geier</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Schlessinger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gable</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Sali</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Giacomini</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Structure-based ligand discovery for the large-neutral amino acid transporter 1, LAT-1</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2013</year>
<volume>110</volume>
<issue>14</issue>
<fpage>5480</fpage>
<lpage>5485</lpage>
<pub-id pub-id-type="pmid">23509259</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uchino</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Wempe</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Chairoungdua</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Morimoto</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Anders</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition</article-title>
<source/>Mol Pharmacol
          <year>2002</year>
<volume>61</volume>
<issue>4</issue>
<fpage>729</fpage>
<lpage>737</lpage>
<pub-id pub-id-type="pmid">11901210</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wiriyasermkul</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Quan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ohgaki</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Okuda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kusakizako</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nishizawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Oda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ishitani</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakane</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shirouzu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nagamori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nureki</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc</article-title>
<source/>Nat Struct Mol Biol
          <year>2019</year>
<volume>26</volume>
<issue>6</issue>
<fpage>510</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="pmid">31160781</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Napolitano</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Galluccio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Scalise</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Parravicini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Palazzolo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Eberini</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Indiveri</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Novel insights into the transport mechanism of the human amino acid transporter LAT1 (SLC7A5). Probing critical residues for substrate translocation</article-title>
<source/>Biochim Biophys Acta Gen Subj
          <year>2017</year>
<volume>1861</volume>
<issue>4</issue>
<fpage>727</fpage>
<lpage>736</lpage>
<pub-id pub-id-type="pmid">28088504</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fagerberg</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hallstrom</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Oksvold</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kampf</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Djureinovic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Odeberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Habuka</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tahmasebpoor</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Danielsson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Edlund</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Asplund</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sjostedt</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lundberg</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Szigyarto</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Skogs</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takanen</surname>
<given-names>JO</given-names>
</name>
<name>
<surname>Berling</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tegel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mulder</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schwenk</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lindskog</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Danielsson</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mardinoglu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sivertsson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>von Feilitzen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Forsberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zwahlen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Navani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huss</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ponten</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Uhlen</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics</article-title>
<source/>Mol Cell Proteomics
          <year>2014</year>
<volume>13</volume>
<issue>2</issue>
<fpage>397</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="pmid">24309898</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verrey</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Closs</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Palacin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>CATs and HATs: the SLC7 family of amino acid transporters</article-title>
<source/>Pflugers Arch
          <year>2004</year>
<volume>447</volume>
<issue>5</issue>
<fpage>532</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="pmid">14770310</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fotiadis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Palacin</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The SLC3 and SLC7 families of amino acid transporters</article-title>
<source/>Mol Asp Med
          <year>2013</year>
<volume>34</volume>
<issue>2–3</issue>
<fpage>139</fpage>
<lpage>158</lpage>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duelli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Enerson</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Gerhart</surname>
<given-names>DZ</given-names>
</name>
<name>
<surname>Drewes</surname>
<given-names>LR</given-names>
</name>
</person-group>
<article-title>Expression of large amino acid transporter LAT1 in rat brain endothelium</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2000</year>
<volume>20</volume>
<issue>11</issue>
<fpage>1557</fpage>
<lpage>1562</lpage>
<pub-id pub-id-type="pmid">11083230</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Puris</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Peltokangas</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Auriola</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kanninen</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Koistinaho</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Ruponen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vellonen</surname>
<given-names>KS</given-names>
</name>
</person-group>
<article-title>Alzheimer's disease phenotype or inflammatory insult does not Alter function of L-type amino acid transporter 1 in mouse blood-brain barrier and primary astrocytes</article-title>
<source/>Pharm Res
          <year>2018</year>
<volume>36</volume>
<issue>1</issue>
<fpage>17</fpage>
<pub-id pub-id-type="pmid">30488131</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papin-Michault</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bonnetaud</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dufour</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Almairac</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Coutts</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Patouraux</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Virolle</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Darcourt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Burel-Vandenbos</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Study of LAT1 expression in brain metastases: towards a better understanding of the results of positron emission tomography using amino acid tracers</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<issue>6</issue>
<fpage>e0157139</fpage>
<pub-id pub-id-type="pmid">27276226</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wittmann</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mohacsik</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Balkhi</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Gereben</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lechan</surname>
<given-names>RM</given-names>
</name>
</person-group>
<article-title>Endotoxin-induced inflammation down-regulates L-type amino acid transporter 1 (LAT1) expression at the blood-brain barrier of male rats and mice</article-title>
<source/>Fluids Barriers CNS
          <year>2015</year>
<volume>12</volume>
<fpage>21</fpage>
<pub-id pub-id-type="pmid">26337286</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tachikawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katayama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Terasaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hosoya</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>L-type amino acid transporter 1-mediated L-leucine transport at the inner blood-retinal barrier</article-title>
<source/>Invest Ophthalmol Vis Sci
          <year>2005</year>
<volume>46</volume>
<issue>7</issue>
<fpage>2522</fpage>
<lpage>2530</lpage>
<pub-id pub-id-type="pmid">15980244</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kaira</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Oriuchi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tominaga</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yanagitani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sunaga</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ishizuka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nagamori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Promchan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer</article-title>
<source/>Anticancer Res
          <year>2010</year>
<volume>30</volume>
<issue>12</issue>
<fpage>4819</fpage>
<lpage>4828</lpage>
<pub-id pub-id-type="pmid">21187458</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaira</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Oriuchi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yanagitani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sunaga</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hisada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kawashima</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Iijima</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ishizuka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung</article-title>
<source/>Pathol Res Pract
          <year>2008</year>
<volume>204</volume>
<issue>8</issue>
<fpage>553</fpage>
<lpage>561</lpage>
<pub-id pub-id-type="pmid">18440724</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Tiffen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Lehman</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Ritchie</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Fazli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Metierre</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gleave</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Rasko</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Holst</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development</article-title>
<source/>J Natl Cancer Inst
          <year>2013</year>
<volume>105</volume>
<issue>19</issue>
<fpage>1463</fpage>
<lpage>1473</lpage>
<pub-id pub-id-type="pmid">24052624</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maimaiti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sugiura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rii</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Imamura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Furihata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Higuchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sazuka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kaneda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kyprianou</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ikehara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Anzai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ichikawa</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma</article-title>
<source/>Sci Rep
          <year>2020</year>
<volume>10</volume>
<issue>1</issue>
<fpage>1292</fpage>
<pub-id pub-id-type="pmid">31992742</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yanagisawa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ichinoe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mikami</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakada</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hana</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Koizumi</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Okayasu</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas</article-title>
<source/>J Clin Pathol
          <year>2012</year>
<volume>65</volume>
<issue>11</issue>
<fpage>1019</fpage>
<lpage>1023</lpage>
<pub-id pub-id-type="pmid">22813728</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoshi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Uchida</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tachikawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ohtsuki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Terasaki</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset</article-title>
<source/>J Pharm Sci
          <year>2013</year>
<volume>102</volume>
<issue>9</issue>
<fpage>3343</fpage>
<lpage>3355</lpage>
<pub-id pub-id-type="pmid">23650139</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uchida</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ohtsuki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Katsukura</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kamiie</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Terasaki</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors</article-title>
<source/>J Neurochem
          <year>2011</year>
<volume>117</volume>
<issue>2</issue>
<fpage>333</fpage>
<lpage>345</lpage>
<pub-id pub-id-type="pmid">21291474</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohtsuki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Hori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Terasaki</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease</article-title>
<source/>Biol Pharm Bull
          <year>2010</year>
<volume>33</volume>
<issue>7</issue>
<fpage>1250</fpage>
<lpage>1252</lpage>
<pub-id pub-id-type="pmid">20606323</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarlungeanu</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Deliu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dotter</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Kara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Janiesch</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Scalise</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Galluccio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tesulov</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Morelli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sonmez</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Bilguvar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ohgaki</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Johansen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Esharif</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ben-Omran</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Topcu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schlessinger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Indiveri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Caglayan</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Gunel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gleeson</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Novarino</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Impaired amino acid transport at the blood brain barrier is a cause of autism Spectrum disorder</article-title>
<source/>Cell.
          <year>2016</year>
<volume>167</volume>
<issue>6</issue>
<fpage>1481</fpage>
<lpage>1494</lpage>
<pub-id pub-id-type="pmid">27912058</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<mixed-citation publication-type="other">Salisbury TB, Arthur S. The Regulation and Function of the L-Type Amino Acid Transporter 1 (LAT1) in Cancer. Int J Mol Sci. 2018;19(8).</mixed-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The role of L-type amino acid transporter 1 in human tumors</article-title>
<source/>Intractable Rare Dis Res
          <year>2015</year>
<volume>4</volume>
<issue>4</issue>
<fpage>165</fpage>
<lpage>169</lpage>
<pub-id pub-id-type="pmid">26668776</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<mixed-citation publication-type="other">Hafliger P, Charles RP. The L-Type Amino Acid Transporter LAT1-An Emerging Target in Cancer. Int J Mol Sci. 2019;20(10).</mixed-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Anzai</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment</article-title>
<source/>World J Gastrointest Oncol
          <year>2017</year>
<volume>9</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="pmid">28144396</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cibrian</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Castillo-Gonzalez</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fernandez-Gallego</surname>
<given-names>N</given-names>
</name>
<name>
<surname>de la Fuente</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jorge</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Saiz</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Punzon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ramirez-Huesca</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vicente-Manzanares</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fresno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dauden</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fraga-Fernandez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vazquez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Aragones</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sanchez-Madrid</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Targeting L-type amino acid transporter 1 in innate and adaptive T cells efficiently controls skin inflammation</article-title>
<source/>J Allergy Clin Immunol
          <year>2020</year>
<volume>145</volume>
<issue>1</issue>
<fpage>199</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="pmid">31605740</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alexander</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Schwartzman</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Grothusen</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>SW</given-names>
</name>
</person-group>
<article-title>Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP parkinsonian monkeys</article-title>
<source/>Neurology.
          <year>1994</year>
<volume>44</volume>
<issue>8</issue>
<fpage>1491</fpage>
<lpage>1499</lpage>
<pub-id pub-id-type="pmid">8058155</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cucca</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mazzucco</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bursomanno</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Antonutti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Di Girolamo</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Pizzolato</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Koscica</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gigli</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Catalan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Biolo</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Amino acid supplementation in l-dopa treated Parkinson's disease patients</article-title>
<source/>Clin Nutr
          <year>2015</year>
<volume>34</volume>
<issue>6</issue>
<fpage>1189</fpage>
<lpage>1194</lpage>
<pub-id pub-id-type="pmid">25660414</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Augustyn</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Finke</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zur</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Heeren</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Chien</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Giacomini</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Colas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schlessinger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs</article-title>
<source/>Bioorg Med Chem Lett
          <year>2016</year>
<volume>26</volume>
<issue>11</issue>
<fpage>2616</fpage>
<lpage>2621</lpage>
<pub-id pub-id-type="pmid">27106710</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagamori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wiriyasermkul</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Okuda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kojima</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hari</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kiyonaka</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tominaga</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ohgaki</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Structure-activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling</article-title>
<source/>Amino Acids
          <year>2016</year>
<volume>48</volume>
<issue>4</issue>
<fpage>1045</fpage>
<lpage>1058</lpage>
<pub-id pub-id-type="pmid">26724922</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ylikangas</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Malmioja</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Peura</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nwachukwu</surname>
<given-names>EO</given-names>
</name>
<name>
<surname>Leppanen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Laine</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rautio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lahtela-Kakkonen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Poso</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1)</article-title>
<source/>ChemMedChem.
          <year>2014</year>
<volume>9</volume>
<issue>12</issue>
<fpage>2699</fpage>
<lpage>2707</lpage>
<pub-id pub-id-type="pmid">25205473</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ylikangas</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Peura</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Malmioja</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Leppanen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Laine</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Poso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lahtela-Kakkonen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rautio</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion</article-title>
<source/>Eur J Pharm Sci
          <year>2013</year>
<volume>48</volume>
<issue>3</issue>
<fpage>523</fpage>
<lpage>531</lpage>
<pub-id pub-id-type="pmid">23228412</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zur</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Chien</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Augustyn</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Flint</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heeren</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Finke</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Giacomini</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Colas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schlessinger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>LAT1 activity of carboxylic acid bioisosteres: evaluation of hydroxamic acids as substrates</article-title>
<source/>Bioorg Med Chem Lett
          <year>2016</year>
<volume>26</volume>
<issue>20</issue>
<fpage>5000</fpage>
<lpage>5006</lpage>
<pub-id pub-id-type="pmid">27624080</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puris</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Auriola</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery</article-title>
<source/>Eur J Pharm Sci
          <year>2019</year>
<volume>129</volume>
<fpage>99</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">30625368</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puris</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Petsalo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>L-type amino acid transporter 1 utilizing prodrugs: how to achieve effective brain delivery and low systemic exposure of drugs</article-title>
<source/>J Control Release
          <year>2017</year>
<volume>261</volume>
<fpage>93</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="pmid">28662899</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chien</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Colas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Finke</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Springer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stoner</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zur</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Venteicher</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Flint</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Augustyn</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Heeren</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Anthony</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fotiadis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schlessinger</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Giacomini</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>Reevaluating the substrate specificity of the L-type amino acid transporter (LAT1)</article-title>
<source/>J Med Chem
          <year>2018</year>
<volume>61</volume>
<issue>16</issue>
<fpage>7358</fpage>
<lpage>7373</lpage>
<pub-id pub-id-type="pmid">30048132</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickens</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Antonyuk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Giannoudis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Radisch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hasnain</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Pirmohamed</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Transport of gabapentin by LAT1 (SLC7A5)</article-title>
<source/>Biochem Pharmacol
          <year>2013</year>
<volume>85</volume>
<issue>11</issue>
<fpage>1672</fpage>
<lpage>1683</lpage>
<pub-id pub-id-type="pmid">23567998</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Bree</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Audus</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Borchardt</surname>
<given-names>RT</given-names>
</name>
</person-group>
<article-title>Carrier-mediated transport of baclofen across monolayers of bovine brain endothelial cells in primary culture</article-title>
<source/>Pharm Res
          <year>1988</year>
<volume>5</volume>
<issue>6</issue>
<fpage>369</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="pmid">3244648</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jalkanen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lehtonen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Forsberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Laine</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ropponen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Leppanen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Knuuti</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rautio</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Brain uptake of ketoprofen-lysine prodrug in rats</article-title>
<source/>Int J Pharm
          <year>2010</year>
<volume>399</volume>
<issue>1–2</issue>
<fpage>121</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="pmid">20727958</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Laine</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ropponen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Leppanen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mannila</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nevalainen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Savolainen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jarvinen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rautio</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Large neutral amino acid transporter enables brain drug delivery via prodrugs</article-title>
<source/>J Med Chem
          <year>2008</year>
<volume>51</volume>
<issue>4</issue>
<fpage>932</fpage>
<lpage>936</lpage>
<pub-id pub-id-type="pmid">18217702</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Killian</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Hermeling</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chikhale</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Targeting the cerebrovascular large neutral amino acid transporter (LAT1) isoform using a novel disulfide-based brain drug delivery system</article-title>
<source/>Drug Deliv
          <year>2007</year>
<volume>14</volume>
<issue>1</issue>
<fpage>25</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="pmid">17107928</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peura</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Malmioja</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Leppanen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hamalainen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Forsberg</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rautio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Laine</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine</article-title>
<source/>Pharm Res
          <year>2013</year>
<volume>30</volume>
<issue>10</issue>
<fpage>2523</fpage>
<lpage>2537</lpage>
<pub-id pub-id-type="pmid">24137801</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peura</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Malmioja</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Laine</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Leppanen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Isotalo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rautio</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery</article-title>
<source/>Mol Pharm
          <year>2011</year>
<volume>8</volume>
<issue>5</issue>
<fpage>1857</fpage>
<lpage>1866</lpage>
<pub-id pub-id-type="pmid">21770378</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huttunen</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Aufderhaar</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Denny</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Spicer</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>L-type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors</article-title>
<source/>Int J Pharm
          <year>2016</year>
<volume>498</volume>
<issue>1–2</issue>
<fpage>205</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="pmid">26705152</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walker</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nicholls</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Drug delivery via active transport at the blood-brain barrier: affinity of a prodrug of phosphonoformate for the large amino acid transporter</article-title>
<source/>Int J Pharm
          <year>1994</year>
<volume>104</volume>
<issue>2</issue>
<fpage>157</fpage>
<lpage>167</lpage>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonina</surname>
<given-names>FP</given-names>
</name>
<name>
<surname>Arenare</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Palagiano</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Saija</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nava</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Trombetta</surname>
<given-names>D</given-names>
</name>
<name>
<surname>de Caprariis</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs</article-title>
<source/>J Pharm Sci
          <year>1999</year>
<volume>88</volume>
<issue>5</issue>
<fpage>561</fpage>
<lpage>567</lpage>
<pub-id pub-id-type="pmid">10229650</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balakrishnan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jain-Vakkalagadda</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pal</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mitra</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>Carrier mediated uptake of L-tyrosine and its competitive inhibition by model tyrosine linked compounds in a rabbit corneal cell line (SIRC)--strategy for the design of transporter/receptor targeted prodrugs</article-title>
<source/>Int J Pharm
          <year>2002</year>
<volume>247</volume>
<issue>1–2</issue>
<fpage>115</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="pmid">12429490</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Peura</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vernerova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leppanen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Karkkainen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lehtonen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rautio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Amino acid Promoieties Alter Valproic acid pharmacokinetics and enable extended brain exposure</article-title>
<source/>Neurochem Res
          <year>2016</year>
<volume>41</volume>
<issue>10</issue>
<fpage>2797</fpage>
<lpage>2809</lpage>
<pub-id pub-id-type="pmid">27412117</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pickering</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Spicer</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Denny</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Systemic and brain pharmacokinetics of Perforin inhibitor Prodrugs</article-title>
<source/>Mol Pharm
          <year>2016</year>
<volume>13</volume>
<issue>7</issue>
<fpage>2484</fpage>
<lpage>2491</lpage>
<pub-id pub-id-type="pmid">27266990</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huttunen</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Aufderhaar</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Denny</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Spicer</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>L-Type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors</article-title>
<source/>Int J Pharm
          <year>2016</year>
<volume>498</volume>
<issue>1–2</issue>
<fpage>205</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="pmid">26705152</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puris</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>de Lange</surname>
<given-names>ECM</given-names>
</name>
<name>
<surname>Auriola</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hammarlund-Udenaes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Loryan</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular Targets</article-title>
<source/>Mol Pharm.
          <year>2019</year>
<volume>16</volume>
<issue>7</issue>
<fpage>3261</fpage>
<lpage>3274</lpage>
<pub-id pub-id-type="pmid">31180686</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huttunen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Peltokangas</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gynther</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Natunen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hiltunen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Auriola</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ruponen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vellonen</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>L-type amino acid transporter 1 (LAT1/Lat1)-utilizing Prodrugs can improve the delivery of drugs into neurons</article-title>
<source/>Astrocytes and Microglia Sci Rep
          <year>2019</year>
<volume>9</volume>
<issue>1</issue>
<fpage>12860</fpage>
<pub-id pub-id-type="pmid">31492955</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huttunen</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Identification of human, rat and mouse hydrolyzing enzymes bioconverting amino acid ester prodrug of ketoprofen</article-title>
<source/>Bioorg Chem
          <year>2018</year>
<volume>81</volume>
<fpage>494</fpage>
<lpage>503</lpage>
<pub-id pub-id-type="pmid">30243240</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atluri</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Talluri</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Mitra</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>Functional activity of a large neutral amino acid transporter (LAT) in rabbit retina: a study involving the in vivo retinal uptake and vitreal pharmacokinetics of L-phenyl alanine</article-title>
<source/>Int J Pharm
          <year>2008</year>
<volume>347</volume>
<issue>1–2</issue>
<fpage>23</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">17686592</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Usui</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kubo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Akanuma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hosoya</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Beta-alanine and l-histidine transport across the inner blood-retinal barrier: potential involvement in L-carnosine supply</article-title>
<source/>Exp Eye Res
          <year>2013</year>
<volume>113</volume>
<fpage>135</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="pmid">23773890</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katragadda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gunda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hariharan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mitra</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections</article-title>
<source/>Int J Pharm
          <year>2008</year>
<volume>359</volume>
<issue>1–2</issue>
<fpage>15</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="pmid">18472234</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suresh</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Xiadong</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ravi</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Mitra</surname>
<given-names>AK</given-names>
</name>
</person-group>
<article-title>Small neutral amino acid Ester Prodrugs of acyclovir targeting amino acid transporters on the cornea: possible antiviral agents against ocular HSV-1 infections</article-title>
<source/>Ophthalmol Eye Dis
          <year>2010</year>
<volume>2</volume>
<fpage>43</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">23861613</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akanuma</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Yamakoshi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sugouchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kubo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hartz</surname>
<given-names>AMS</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hosoya</surname>
<given-names>KI</given-names>
</name>
</person-group>
<article-title>Role of l-type amino acid transporter 1 at the inner blood-retinal barrier in the blood-to-retina transport of gabapentin</article-title>
<source/>Mol Pharm
          <year>2018</year>
<volume>15</volume>
<issue>6</issue>
<fpage>2327</fpage>
<lpage>2337</lpage>
<pub-id pub-id-type="pmid">29688723</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shennan</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gow</surname>
<given-names>IF</given-names>
</name>
<name>
<surname>Travers</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>L-leucine transport in human breast cancer cells (MCF-7 and MDA-MB-231): kinetics, regulation by estrogen and molecular identity of the transporter</article-title>
<source/>Biochim Biophys Acta
          <year>2004</year>
<volume>1664</volume>
<issue>2</issue>
<fpage>206</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="pmid">15328053</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Tangtrongsup</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chairoungdua</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Babu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tachampa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Anzai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Iribe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells</article-title>
<source/>Biochim Biophys Acta
          <year>2002</year>
<volume>1565</volume>
<issue>1</issue>
<fpage>112</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="pmid">12225859</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Raoof</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Greenson</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Bourner</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Orringer</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Beer</surname>
<given-names>DG</given-names>
</name>
</person-group>
<article-title>L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma</article-title>
<source/>Neoplasia.
          <year>2004</year>
<volume>6</volume>
<issue>1</issue>
<fpage>74</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">15068672</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greig</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Momma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sweeney</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>QR</given-names>
</name>
<name>
<surname>Rapoport</surname>
<given-names>SI</given-names>
</name>
</person-group>
<article-title>Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system</article-title>
<source/>Cancer Res
          <year>1987</year>
<volume>47</volume>
<issue>6</issue>
<fpage>1571</fpage>
<lpage>1576</lpage>
<pub-id pub-id-type="pmid">3815357</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hosoya</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kyoko</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Toyooka</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Orihashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tomi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tachikawa</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Evaluation of amino acid-mustard transport as L-type amino acid transporter 1 (LAT1)-mediated alkylating agents</article-title>
<source/>Biol Pharm Bull
          <year>2008</year>
<volume>31</volume>
<issue>11</issue>
<fpage>2126</fpage>
<lpage>2130</lpage>
<pub-id pub-id-type="pmid">18981585</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haines</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Fuller</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vistica</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Marquez</surname>
<given-names>VE</given-names>
</name>
</person-group>
<article-title>Selective cytotoxicity of a system L specific amino acid nitrogen mustard</article-title>
<source/>J Med Chem
          <year>1987</year>
<volume>30</volume>
<issue>3</issue>
<fpage>542</fpage>
<lpage>547</lpage>
<pub-id pub-id-type="pmid">3820226</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Greig</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Vistica</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Rapoport</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>QR</given-names>
</name>
</person-group>
<article-title>Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier</article-title>
<source/>Cancer Chemother Pharmacol
          <year>1991</year>
<volume>29</volume>
<issue>2</issue>
<fpage>89</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="pmid">1760863</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matharu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Oki</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Worthen</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>QR</given-names>
</name>
<name>
<surname>Crooks</surname>
<given-names>PA</given-names>
</name>
</person-group>
<article-title>Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter (system LAT1) of the blood-brain barrier</article-title>
<source/>Bioorg Med Chem Lett
          <year>2010</year>
<volume>20</volume>
<issue>12</issue>
<fpage>3688</fpage>
<lpage>3691</lpage>
<pub-id pub-id-type="pmid">20466543</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Earhart</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>H</given-names>
</name>
<name>
<surname>McGovren</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Prevention of central nervous system toxicity of the antitumor antibiotic acivicin by concomitant infusion of an amino acid mixture</article-title>
<source/>Cancer Res
          <year>1990</year>
<volume>50</volume>
<issue>17</issue>
<fpage>5475</fpage>
<lpage>5480</lpage>
<pub-id pub-id-type="pmid">2386952</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<mixed-citation publication-type="other">Hong S, Fang Z, Jung HY, Yoon JH, Hong SS, Maeng HJ. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties. Molecules. 2018;23(10).</mixed-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Si</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ci</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumors</article-title>
<source/>Cancer Sci
          <year>2015</year>
<volume>106</volume>
<issue>6</issue>
<fpage>747</fpage>
<lpage>756</lpage>
<pub-id pub-id-type="pmid">25867020</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Subudhi</surname>
<given-names>BB</given-names>
</name>
</person-group>
<article-title>Development and characterization of lysine-methotrexate conjugate for enhanced brain delivery</article-title>
<source/>Drug Deliv.
          <year>2016</year>
<volume>23</volume>
<issue>7</issue>
<fpage>2327</fpage>
<lpage>2337</lpage>
<pub-id pub-id-type="pmid">25475953</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>An</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Amino acid metabolism abnormity and microenvironment variation mediated targeting and controlled Glioma chemotherapy</article-title>
<source/>Small.
          <year>2016</year>
<volume>12</volume>
<issue>40</issue>
<fpage>5633</fpage>
<lpage>5645</lpage>
<pub-id pub-id-type="pmid">27571928</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhunia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vangala</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bhattacharya</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ravuri</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Kuncha</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chakravarty</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sistla</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chaudhuri</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Large amino acid transporter 1 selective liposomes of l-DOPA functionalized Amphiphile for combating Glioblastoma</article-title>
<source/>Mol Pharm
          <year>2017</year>
<volume>14</volume>
<issue>11</issue>
<fpage>3834</fpage>
<lpage>3847</lpage>
<pub-id pub-id-type="pmid">28958145</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: toward a novel active targeting strategy in breast cancer therapy</article-title>
<source/>Nanomedicine.
          <year>2017</year>
<volume>13</volume>
<issue>3</issue>
<fpage>987</fpage>
<lpage>998</lpage>
<pub-id pub-id-type="pmid">27890657</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting</article-title>
<source/>Colloids Surf B Biointerfaces
          <year>2016</year>
<volume>141</volume>
<fpage>260</fpage>
<lpage>267</lpage>
<pub-id pub-id-type="pmid">26859117</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ong</surname>
<given-names>ZY</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nabavi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Regoutz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Payne</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Elson</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Dexter</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Dunlop</surname>
<given-names>IE</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>AE</given-names>
</name>
</person-group>
<article-title>Multibranched gold nanoparticles with intrinsic LAT-1 targeting capabilities for selective Photothermal therapy of breast Cancer</article-title>
<source/>ACS Appl Mater Interfaces
          <year>2017</year>
<volume>9</volume>
<issue>45</issue>
<fpage>39259</fpage>
<lpage>39270</lpage>
<pub-id pub-id-type="pmid">29058874</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langstrom</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Antoni</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gullberg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Halldin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Malmborg</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nagren</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rimland</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Svard</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Synthesis of L- and D-[methyl-11C]methionine</article-title>
<source/>J Nucl Med
          <year>1987</year>
<volume>28</volume>
<issue>6</issue>
<fpage>1037</fpage>
<lpage>1040</lpage>
<pub-id pub-id-type="pmid">3585494</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glaudemans</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Enting</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Heesters</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Dierckx</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>van Rheenen</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Walenkamp</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Slart</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>Value of 11C-methionine PET in imaging brain tumours and metastases</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2013</year>
<volume>40</volume>
<issue>4</issue>
<fpage>615</fpage>
<lpage>635</lpage>
<pub-id pub-id-type="pmid">23232505</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okubo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhen</surname>
<given-names>HN</given-names>
</name>
<name>
<surname>Kawai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nishiyama</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Haba</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tamiya</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas</article-title>
<source/>J Neuro-Oncol
          <year>2010</year>
<volume>99</volume>
<issue>2</issue>
<fpage>217</fpage>
<lpage>225</lpage>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grosu</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Astner</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Riedel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nieder</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wiedenmann</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Heinemann</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Schwaiger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Molls</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wester</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>WA</given-names>
</name>
</person-group>
<article-title>An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C] methionine (MET)-PET in patients with brain gliomas and metastases</article-title>
<source/>Int J Radiat Oncol Biol Phys
          <year>2011</year>
<volume>81</volume>
<issue>4</issue>
<fpage>1049</fpage>
<lpage>1058</lpage>
<pub-id pub-id-type="pmid">21570201</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lahoutte</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Caveliers</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Camargo</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Franca</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ramadan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Veljkovic</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bossuyt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Verrey</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation</article-title>
<source/>J Nucl Med
          <year>2004</year>
<volume>45</volume>
<issue>9</issue>
<fpage>1591</fpage>
<lpage>1596</lpage>
<pub-id pub-id-type="pmid">15347729</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Habermeier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Graf</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sandhofer</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Boissel</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Roesch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Closs</surname>
<given-names>EI</given-names>
</name>
</person-group>
<article-title>System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET)</article-title>
<source/>Amino Acids
          <year>2015</year>
<volume>47</volume>
<issue>2</issue>
<fpage>335</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="pmid">25385314</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becherer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Karanikas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Szabo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zettinig</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Asenbaum</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marosi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Henk</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wunderbaldinger</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Czech</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wadsak</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kletter</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Brain tumour imaging with PET: a comparison between [18F] fluorodopa and [11C]methionine</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2003</year>
<volume>30</volume>
<issue>11</issue>
<fpage>1561</fpage>
<lpage>1567</lpage>
<pub-id pub-id-type="pmid">14579097</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Comparison of 5 different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma: a network Meta-analysis</article-title>
<source/>Clin Nucl Med
          <year>2020</year>
<volume>45</volume>
<fpage>341</fpage>
<lpage>348</lpage>
<pub-id pub-id-type="pmid">32049723</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<mixed-citation publication-type="other">Youland RS, Kitange GJ, Peterson TE, Pafundi DH, Ramiscal JA, Pokorny JL, Giannini C, Laack NN, Parney IF, Lowe VJ, Brinkmann DH, Sarkaria JN. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neuro-Oncol 2013;111(1):11–18.</mixed-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomiyoshi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Amed</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Muhammad</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Higuchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Endo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2- and 3-L-18F-alpha-methyltyrosine using a separation and purification system</article-title>
<source/>Nucl Med Commun
          <year>1997</year>
<volume>18</volume>
<issue>2</issue>
<fpage>169</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="pmid">9076774</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiriyasermkul</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nagamori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tominaga</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Oriuchi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kaira</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kitashoji</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ohgaki</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Endo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Transport of 3-fluoro-L-alpha-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET</article-title>
<source/>J Nucl Med
          <year>2012</year>
<volume>53</volume>
<issue>8</issue>
<fpage>1253</fpage>
<lpage>1261</lpage>
<pub-id pub-id-type="pmid">22743251</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaira</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Oriuchi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Otani</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yanagitani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sunaga</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hisada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ishizuka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dobashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Endou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Endo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study</article-title>
<source/>Clin Cancer Res
          <year>2007</year>
<volume>13</volume>
<issue>21</issue>
<fpage>6369</fpage>
<lpage>6378</lpage>
<pub-id pub-id-type="pmid">17975149</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nobusawa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaira</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miyashita</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Negishi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Oriuchi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Higuchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tsushima</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yokoo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Oyama</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Diagnostic usefulness of (1)(8)F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma</article-title>
<source/>Eur J Nucl Med Mol Imaging
          <year>2013</year>
<volume>40</volume>
<issue>11</issue>
<fpage>1692</fpage>
<lpage>1700</lpage>
<pub-id pub-id-type="pmid">23801167</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nozaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nakatani</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mawatari</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hume</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Hayashinaka</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Doi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>(18)F-FIMP: a LAT1-specific PET probe for discrimination between tumor tissue and inflammation</article-title>
<source/>Sci Rep
          <year>2019</year>
<volume>9</volume>
<issue>1</issue>
<fpage>15718</fpage>
<pub-id pub-id-type="pmid">31673030</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kankaanranta</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Saarilahti</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Makitie</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Valimaki</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tenhunen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Joensuu</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement</article-title>
<source/>Radiother Oncol
          <year>2011</year>
<volume>99</volume>
<issue>1</issue>
<fpage>98</fpage>
<lpage>99</lpage>
<pub-id pub-id-type="pmid">21397966</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawabata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Miyatake</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kuroiwa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Doi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Iida</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miyata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nonoguchi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Michiue</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Inomata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Imahori</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kirihata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Maruhashi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kumada</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Boron neutron capture therapy for newly diagnosed glioblastoma</article-title>
<source/>J Radiat Res
          <year>2009</year>
<volume>50</volume>
<issue>1</issue>
<fpage>51</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">18957828</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barth</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Coderre</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Vicente</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Blue</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>Boron neutron capture therapy of cancer: current status and future prospects</article-title>
<source/>Clin Cancer Res
          <year>2005</year>
<volume>11</volume>
<issue>11</issue>
<fpage>3987</fpage>
<lpage>4002</lpage>
<pub-id pub-id-type="pmid">15930333</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wongthai</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hagiwara</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miyoshi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wiriyasermkul</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ohgaki</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hamase</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nagamori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kanai</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2</article-title>
<source/>Cancer Sci
          <year>2015</year>
<volume>106</volume>
<issue>3</issue>
<fpage>279</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="pmid">25580517</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>